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Abstract 
  
The SERINC family is a highly conserved group of genes which in the human 
genome comprises 5 members, encoding five homologous multipass 
transmembrane proteins. SERINC5, and to a lesser extent SERINC3, are 
powerful inhibitors of Human immunodeficiency virus 1 (HIV-1). SERINC5, 
expressed in virus-producing cells, is incorporated into the envelope of newly 
formed retroviral particles and inhibits an early stage of the virus infection 
process of the target cell, by preventing the delivery of the retroviral core 
into the target cell cytoplasm. 
Nef, an accessory protein of HIV-1, counteracts the antiretroviral activity of 
SERINC5 by promoting its endocytosis, which results in its removal from the 
cell surface, preventing its incorporation into retroviral particles.  
SERINC5 inhibits not only HIV-1, but also other divergent retroviruses, such as 
Murine leukemia virus (MLV). During my Ph.D. studies I demonstrated that 
the S2 auxiliary protein from Equine infectious anemia virus (EIAV) 
functionally resembles Nef and MLV glycoGag and counteracts SERINC5 with 
a similar mechanism. 
While the inhibitory effect of SERINC5 has been established on retroviruses, 
nothing is yet known about its effect on other viruses. Here I describe 
evidence which indicates the possible inhibitory activity of the SERINC gene 
family against other RNA viruses. 
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Chapter 1: Introduction 
 
The Retroviridae family of viruses 
 
1970 was the year in which the central dogma of molecular biology was 
questioned by David Baltimore and Howard Temin; before then, the direction 
of the chain of events that leads to proteins from DNA, going through an RNA 
intermediate, had never been doubted. With the discovery of the reverse 
transcriptase enzyme, that was awarded the Nobel prize for Medicine and 
Physiology, a new world had opened1. 
Reverse transcriptase is a viral gene encoded by Retroviridae, that gave this 
family of viruses the name. We can distinguish three genera: Oncovirinae, 
which comprises Alpharetroviruses (ALV, RSV, AMV, FuSV), Betaretroviruses 
(MMTV, JSRV, SMRV), Deltaretroviruses (HTLV-1, HTLV-2, BLV), 
Epsilonretroviruses (WDSV), Gammaretroviruses (MLV, FeLV, GALV, XMRV); 
Lentiviridae (HIV-1, HIV-2, SIV, BIV, FIV, EIAV) and Spumaviridae represented 
by Foamy viruses (FFV, BFV, SFV) (Figure 1.1). This classification is based on 
genetic similarity within pol genes, even if other features are taken in 
consideration, such as the presence or absence of additional viral genes. 
Another possible classification is based on the type of pathologies caused by 
the retroviral infection; they could be recapitulated in: 
 Oncogenesis (HTLV, BLV) 
 Neurological diseases (HTLV, HIV-1)   
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 Immunodeficiencies (HIV-1, FIV, SIV) 
Figure 1.1  
Phylogeny of retroviruses. 
 Genera that include endogenous genomes are marked with an asterisk. 
 Modified from Retrovirology20063:67DOI: 10.1186/1742-4690-3-67Weiss. 2006 
* 
10 
 
 
 Other retroviruses-induced diseases (lentivirus-induced equine 
anemia, lentiviral infections of sheep and goats, wasting induced 
by avian retroviruses, anemia induced by FeLV-C, osteoporosis 
induced by ALV and MAV). 
Association between cancer and retrovirus infection was hypothesized in the 
early 1900, when Peyton Rous studied virus coming from chicken 
fibrosarcoma2. Later, sarcomas, hematopoietic tumours and some examples 
of carcinoma were found to be caused by viruses which belong to this viral 
family. 
In the genome of some retroviruses it is possible to find additional factors 
called viral oncogenes (v-onc genes), originated from recombination with 
cellular proto-oncogenes. The discovery of these additional viral proteins 
helped to clarify not only their role during carcinogenesis but also their 
physiological function. Retroviruses therefore provided a unique tool to 
elucidate molecular mechanisms involved in tumour onset and progression in 
particular, and in host cellular biology in general. 
In most of the cases, insertion of v-onc could hyper-activate cellular pathways 
controlling crucial events of the cell cycle leading to misregulated 
proliferation; although extremely rare insertional mutagenesis could also 
result in inactivation of a tumour suppressor or in expression of aberrant 
chimeric proteins3.   
Different neurological central nervous system diseases could be associated 
with retroviruses in human and in animals (loss of neuronal function due to 
HTLV-1 and HIV-1, amyotrophic lateral sclerosis)3. How viruses can enter the 
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CNS remains still debated, but it seems evident that in the case of HIV-1, the 
virus crosses the blood-brain barrier (BBB) almost immediately after 
infection. One possibility is the so-called “Trojan horse” hypothesis which 
suggests that the virus hides in CD4+ T lymphocytes or monocytes to reach 
the CNS. Once there, accumulation of cytokines and toxic products caused by 
activation of an immune response leads to a progressive neurodegeneration4. 
Many retroviruses display tropism for cells involved in the immune response 
that once infected are eliminated, causing immune suppression. This 
phenomenon was more or less ignored until the dramatic diffusion of AIDS 
and the discovery of HIV-1. Immunodeficiencies could be found in cats and 
non-human primates as a result of FIV and SIV retroviruses and are 
sometimes referred to as feline and simian AIDS, respectively3.  
 As already mentioned, one of the peculiarities amenable to retroviruses, is 
the integration of their genetic information in the genome of the infected 
host; if the event occurs in germ line cells, this modification becomes a 
heritable trait vertically transmitted through generations. It has been 
calculated that up to 8% of the human DNA is composed by no longer active 
retro-elements named endogenous retroviruses (ERV). This phenomenon 
originated millions of years ago and was quite common during evolution with 
at least 98.000 calculated insertions found to be present in all vertebrate 
genome investigated5. 
Usually considered as “junk material”, the product of accumulation of a great 
number of mutations, frameshifts and deletions, and no longer able to 
produce infectious particles, their reactivation is possible and a variety of 
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autoimmune diseases are suggested to be associated with this phenomenon 
(lupus erythematosus, rheumatoid arthritis, multiple sclerosis)6,7. 
 In some rare cases they developed a role in helping the host organism with 
physiological events, such as the placenta formation. This is the case of HERV-
W encoding for syncytin8. 
 
Genetic structure 
 
In each virion there are two RNA molecules each ranging in size from 7 to 13 
kb depending on the genera. Thanks to the diploid nature of the genetic 
information, a high-rate of recombination can be found in this particular viral 
family. 
Different modifications are added to the viral RNA with the insertion of a cap 
and a poly-A at the 5’ and 3’ ends, making the transcript similar to the host 
mRNA. It is possible to recognize two different populations of newly formed 
RNA: one that remains unspliced, and acts as genomic RNA and as mRNA for 
translation of Gag and Pol. The other which is processed and spliced to 
generate the envelope protein. The proper ratio of spliced and unspliced RNA 
is fundamental to achieve efficient replication.  
In viral assembly, the genomic RNA is identified as the one to be included in 
the progeny virus by virtue of a complex sequence in the leader region, called 
ψ (from the original work on MLV) or E (for encapsidation, in the Spleen 
necrosis virus system). In the mature virion, the diploid RNA genomes are  
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held together by a sequence called the “dimer linkage,” which is in the leader 
region or in some cases in gag. 
In all retroviruses, reverse transcription starts with association between the 
tRNA primer and the complementary “primer-binding site” (PBS) in the viral 
sequence.  
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Figure 1.2  
 Retroviruses genome and viral particle.  
Modified from www.tutorhelpdesk.com 
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Different retroviruses evolved to use different tRNAs as primers (tRNALys for 
HIV-1, tRNAPro for MLV). As a tRNA is used as primer for synthesis of the 
“minus” strand, an RNA fragment derived from the polypurine tract (PPT) is 
used as primer for the “plus” strand.  
Interestingly, in retroviral particles it is also possible to detect a small amount 
of DNA: in HIV representing about 0.1% of the amount of genomic RNA (early 
products of reverse transcription). In Spumaviruses the situation changes 
with a large proportion of reverse transcripts present in the virion. 
Accordingly, the reverse transcriptase sequence of this viral genus is most 
distant from all other retroviral genera. 
From the reverse transcription process, viral DNA is generated and integrated 
in the cellular genome leading to the formation of the so called “provirus”. 
Differences between virus and provirus genomes are attributable to two 
identical long terminal repeats (LTR), added during the reverse-transcription 
and resulting from the duplication of U3 and U5. Each LTR is formed by U3, R 
and U5. The LTR in 5’ drives the production of viral RNA3 (Figure 1.2). 
 
The Retroviridae life cycle 
 
In the Retroviridae family, genetic information is encoded in two identical 
single-stranded positive-sense RNA molecules. With its function as RNA-
dependent DNA polymerase, reverse transcriptase is able, once in the 
cytoplasm of the infected cell, to convert viral RNA into DNA which will be 
integrated into the genome of the host cell and translated together with 
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cellular genes, allowing the production of proteins necessary for the 
assembly of viral particles. 
The enzyme is encoded by the pol gene (driving the expression of a 
polyprotein that includes even integrase and protease), which along with gag 
(encoding for structural proteins) and env, is considered a fundamental 
component of the minimal genome present in all Retroviridae family 
members. 
Reverse transcription and integration are only two of many steps occurring 
during the journey that culminates with the formation of a new virus particle. 
To briefly have an overview, the events occurring during the viral life cycle 
can be recapitulated in:  
 Binding of viral envelope glycoproteins to cellular surface 
receptors. 
 This interaction triggers a conformational change allowing the physical 
contact between the two membranes and allowing the formation of a fusion 
pore that drives the entry of the virus inside the cell cytosol3. Alternatively, 
for example in the case of ALV or EIAV, the fusogenic property of the 
envelope is dispatched only under low pH conditions of the endosomal 
compartment. In this situation the retroviral core is internalized and directly 
delivered within the cell9,10. Micropinocytosis could mediate the entry 
process for amphotropic MLV and for Ebolavirus11,12. Rafts microdomains 
have been demonstrated to be the preferential site on the cell membrane for 
viral entry, with accumulation of both the envelope glycoproteins and the 
host receptors13. 
 Uncoating of the viral capsid and reverse transcription.  
17 
 
Once the viral RNA is released in the cell cytoplasm, dissociation of capsid 
and reverse transcription occurs concurrently with the formation of the 
reverse transcription complex (RTCs) and the pre-integration complex (PICs). 
The reverse transcription of the viral genome is a key step taking place at an 
early phase of the viral life cycle for all retroviruses studied.  
 Nuclear import and integration. 
Nuclear import is governed essentially by the size of the nuclear pores and 
the interaction between nucleoproteins (NUPs) and specific carrier proteins.  
This is the main reason why some retroviruses are able to reach the nucleus 
only during mitosis when the nuclear membrane is dissolved (for example 
MLV)14.  
Integration happens thanks to the integrase enzyme that inserts a double-
strand break in the host DNA sequence, and promotes the formation of a 
new phosphodiester bond between viral DNA and the cellular genome. Nicks 
are filled by the host DNA repair machinery. 
The specific site in which the process occurs seems not to be random, but 
affected by chromatin architecture15.   
 Transcription, export and translation of viral RNA.  
All these events take advantage of the already existing cellular machinery 
(controlling for example trafficking or splicing) which process the integrated 
viral gene as a part of the host genome. 
 Assembly, budding and maturation.  
According to the different retroviral origins, assembly take place in the  
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Figure 1.3 
Different events in the life cycle of retroviruses are illustrated.  
Viral entry into cells involves the following steps: binding to a specific receptor on the cell 
surface; membrane fusion either at the plasma membrane or from endosomes (not shown); 
release of the viral core and partial uncoating; reverse transcription; transit through the 
cytoplasm and nuclear entry; and integration into cellular DNA to give a provirus. b) Viral exit 
involves the following steps: transcription by RNA polymerase II (RNAPII); splicing and nuclear 
export of viral RNA; translation of viral proteins, Gag assembly and RNA packaging; budding 
through the cell membrane; and release from the cell surface and virus maturation. Stoye, J. P.,   
Nature Reviews Microbiology 10, 395-406 (2012)  
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cell cytoplasm (for example MMTV) or on the cell surface (for example MLV) 
and it is mediated by the Gag and Gag-Pol polyproteins. During the budding 
process, lipids from the host cell plasma membrane will be incorporated in 
the viral envelope becoming an integral part of the virus16.  
After assembly, the immature morphology of the viral particle is redefined by 
the viral protease that gives the virion the final shape after or during budding 
3(Figure 1.3). 
Due to the complexity of the events involved, the majority of the retrovirus 
family members developed a number of regulatory and accessory proteins, 
along with Gag, Pol and Env, with the function of performing additional 
activities in the virus life cycle and to modify the local environment within the 
infected cells to ensure viral persistence, replication, dissemination and 
transmission. These factors are often needed to overcome both non-specific 
cellular barriers (cell membrane, actin cortex, nuclear envelope) and specific 
antiviral host factors. 
 
HIV-1 
 
HIV-1 and HIV-2 originated through cross species transmission of simian 
retroviruses from monkeys to human, which occurred several times over 
decades. 
HIV-1 includes four groups: M, N, O and P; with M recognized as the cause of 
the pandemic diffusion of AIDS (almost 90% of the infected patients) (Figure 
1.4). 
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Figure 1.4 
Phylogenetic Tree of the SIV and HIV.  
Viruses Depicted: Human HIV-1 M (Main) group, including reference strains from subtypes A-J. 
Group M is responsible for the pandemic. HIV-1 O (Outlier) group, most commonly found in West 
Africa HIV-1 N (Not-M, Not-O) group, found in a very small number of individuals in West Africa 
HIV-1 M group reference strains: A_UG.U455, A_KE.Q2317, B_US.JRFL, B_US.WEAU160, 
C_ET.ETH2220, C_IN.21068, D_ZR.NDK, D_ZR.ELI, F_FI.FIN6393, F_BE.VI850, G_SE.SE6165, 
G_BE.DRCBL, H_CF.90CF056, H_BE.VI997, J_SE.SE91733, J_SE.SE92809, and CRF01 AE_CF.90CF402 
and AE_TH.CM240, which are subtype A in pol. HIV-1 N group: N_CM.YBF30 HIV-1 O group: 
O_CM.ANT70, O_CM.MVP5180 HIV-2 subtypes A and B: H2A_DE.BEN, H2A_SN.ST, H2B_GH.D205, 
and H2B_CI.EHO Simian SIVcpz from chimpanzee Pan troglodytes troglodytes (P.t.t.): SIVcpz.GAB, 
SIVcpz.US, and SIVcpz.Cam3 SIVcpz from chimpanzee Pan troglodytes shweinfuthii (P.t.s.): 
SIVcpz.ANT SIV African Green Monkey (SIVagm): Tantalus (TAN): SIVagm.TAN1 Vervet (VER): 
SIVagm.VERTYO, SIVagm.VERAGM3, SIVagm.VER9063, SIVagm.VER155 Grivet (GRI): 
SIVagm.GRI677 Sabaeus (SAB): SIVagm.SAB1C SIV Sooty Mangaby (SIVsm) (also found in captive 
macaques): SIVsm.mac251, SIVsm.smm9 SIV L’hoest: SIV.LHOEST SIV Mandrill: SIV.MNDGB1 SIV 
Sun: SIV.SUN 
Based on work by the Theoretical Biology and Biophysics Group, Los Alamos National Laboratory. 
This image belong to Thomas Splettstoesse 
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Human immunodeficiency virus type 1 (HIV-1) is a retrovirus belonging to the 
lentivirus genus. It is probably the best-known virus of the entire family since 
it is the etiological agent of acquired immune deficiency syndrome (AIDS), 
which caused 39 million deaths from 1983, when it was first identified by 
Montagnier’s group. The disease is characterized by the progressive decay of 
the immune system leading to death of the infected patients caused by 
opportunistic infections or cancer. 
Natural cellular targets of the virus are lymphoid cells (CD4+ T cells, 
macrophages, dendritic cells), expressing the CD4 receptor, along with CCR5 
and CXCR4 co-receptors, used for entry. Once HIV-1 integrates in the cellular 
genome, it undergoes a latency phase during which the immune system is 
unable to detect the infection. During this phase, that can proceed for a long 
time, patients are infectious but do not show any symptom of the disease. 
Only when the CD4+ lymphocyte count reaches a level <200 per ml it can be 
defined as AIDS17,18 (Figure 1.5). 
During HIV-1 progression, a dramatic decrease of lymphocytes is due to the 
effect of infection. In addition, the chronic immune response activation leads 
to an increase in number of activated memory CD4+ T cells, that become 
available for viral infection19.  
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Figure 1.5 
Graph of the typical progression of HIV infection and AIDS. 
https://www.learner.org/courses/biology/archive/images/1925.html 
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HIV genome and accessory proteins  
 
As for all retroviruses, the genome is composed by the three canonical open 
reading frames, gag, pol and env, flanked by several accessory proteins with 
the function of increasing viral spreading and propagation. Apart from Tat 
and Rev, classified as regulatory proteins, (trans-activator of viral-genome 
transcription, Tat, and regulator of splicing, Rev) we can find four additional 
regulatory genes, vif, vpr, vpu and nef. 
The RNA genome is surrounded by capsid and nucleocapsid proteins together 
with essential viral enzymes (reverse transcriptase, integrase, and protease); 
capsid is enclosed in a matrix layer, while the virus is encircled by cellular 
lipids and viral glycoproteins (gp140; gp120) (Table 1). 
Vif (virion infectivity factor) is a cytoplasmic protein of 192 aa, found to be 
required for replication of the virus in non-permissive cells, CD4+ T cells and 
monocyte-derived macrophages (MDMs), and throughout natural 
infection20,21. For long time the role of Vif remained an unresolved question, 
until 2002, when Malim’s group identified a human gene able to inhibit HIV-1 
infection. APOBEC3G, apolipoprotein B messenger RNA–editing enzyme 
catalytic polypeptide-like 322. This protein is a member of an evolutionarily 
maintained family, that in humans includes 7 members23. APOBEC3G is a 
single-strand DNA deaminase incorporated in viral particles and acting at the 
level of target cells. It is able to strongly inhibit replication causing 
hypermutations within the viral genome, and to produce accumulation of 
random G to A transitions. Once reverse transcription occurs, cells are able to 
sense these anomalous products and to drive them to degradation. In 
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addition, insertion of stop codons and missense mutations leads to the 
formation of a virus no longer capable of progressing through the infection 
process24,25. Vif interferes with this mechanism by excluding APOBEC3G from 
the viral particles of the progeny viruses, and mediating its degradation 
thought direct recruitment of the Cullin 5-based E3 ubiquitin ligase 
complex26,27. Viral factors counteracting the APOBEC family members could 
be found in retroviruses able to infect different species: MLV-glycoGag 
counteracts APOBEC3 in mice28,29; Bet, an accessory protein of Spumaviruses, 
counteracts the same protein during mammalian infection in a degradation-
independent manner that needs to be elucidated30. 
Vpr (viral protein R) is a 96 aa protein required for viral replication in non-
dividing cells. It is conserved among human and simian immunodeficiency 
viruses31. Vpr has been shown to be involved in the cell cycle, mediating 
arrest during the G2/M transition32. It interacts with SLX4 and the structure-
specific endonucleases (SSEs). This complex is strictly regulated during the 
cell cycle; up-regulation derived from PLK1 phosphorylation leads to genomic 
instability and to an establishment of a steady state during cell cycle 
progression. Since PLK1 directly cooperates with Vpr, the viral protein allows 
a physical interaction between PLK1 and the SLX4-SSEs complex; PLK1-
mediated aberrant activation of the endonuclease complex culminates with 
misregulation of cell cycle progression and degradation of cDNA coming from 
reverse transcription of the viral genome. At this point the model proposed is 
that the reduction in copy number of RT products makes the host cell unable 
to sense viral infection, failing to activate the interferon-mediated immune 
response and facilitating virus dissemination33.  
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A role for Vpr in facilitating shuttling of the viral c-DNA between the cytosol 
and the nucleus has been proposed by several groups. This hypothesis is 
supported by the observation that along with the amino acid sequence of the 
viral protein, we can recognize two non-canonical nuclear localization signals 
and one nuclear export signal. In addition, experimental data suggesting 
interaction with the RTC/PIC complex were published34–36.  
Lastly, Vpr is responsible for the incorporation of UNG2 uracil glycosylase37,38 
in the viral particles, but the role of this interaction needs to be clarified.  
Retroviruses from HIV-2/SIVsm, SIVrmc, SIVmnd2 have in their genome 
another accessory protein named Vpx39,40. Interestingly, Vpx is the product of 
recombination and duplication of the Vpr ancestral gene41,42. Vpx is able to 
neutralize the effect of SAMHD1, a cellular phosphohydrolase involved in the 
catabolism of dNTP43–45 which  has also an exonuclease activity on ss-RNA46. 
Both events have a clear negative effect on the viral reverse transcription 
process. As already discussed for Vif, Vpx is able to recruit DCA1-DDB1-CUL4-
RBX1 machinery and target SAMHD1 for proteasome degradation47. 
Vpu (viral protein unique) is present in HIV-1 and some SIV isolates. This 
protein is able to prevent virus accumulation on the cell membrane after 
budding of the new-born viral particles.  Virus released is hindered by BST2, 
also called tetherin48. Tetherin is a type-2 transmembrane protein anchored 
to the cell lipid bilayer through a GPI linker49. The evidence that viruses that 
don’t encode for   
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Table 1: HIV-1 proteins and genomic organization 
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this gene have evolved other unrelated proteins to counteract the same 
cellular factor (Nef for the majority of SIV isolates50 and envelope proteins for 
some primate lentiviruses51) suggests how fundamental this activity is. 
Interestingly, Vpu is also involved in CD4 downregulation from the ER surface 
by interaction with cullin1-Skp1 ubiquitin ligase complex52,53.  
Both tetherin and CD4 could be targeted for degradation also through 
recruitment of b-TrCP complex54 with a molecular mechanism which needs to 
be elucidated. 
 
The multifunctional activity of Nef 
 
Nef (Negative factor) is a 27 KDa myristoylated protein encoded only by 
primate lentiviruses; this post–translational modification, along with a 
repetition of basic amino acids present at the N-terminal of the molecule, 
enables its interaction with the inner face of the plasma membrane. The 
complete understanding of all the different mechanisms in which the protein 
is involved and all the cellular interactors are still controversial (Figure 1.6). 
Accordingly, the name of the factor is derived from a controversial 
observation. The first evidence of the expression of a nef ORF, partially 
overlapping with the 3’ UTR region, arrived in 1986 when at least two 
different groups were able to detect antibody targeting this factor during the 
course of natural infection55,56. A study reported that its overexpression 
causes attenuation in viral transcription and virus replication57; only three  
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Figure 1.6 
Nef protein. 
 a) Nef motifs; b) Nef secondary  structure. 
viralzone.expasy.org 
opm.phar.umich.edu 
 
a) 
b) 
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years later, in 1989, it became clear that the observed negative effect was 
due to promotor competition between the LTR in the vector expressing Nef 
and those present in the HIV-1 genome58. 
Nef, as for other HIV-1 accessory proteins, can be dispensable for virus 
replication in vitro but required for efficient viral propagation in vivo59. In 
addition, patients infected with HIV strains depleted of Nef do not progress 
from the symptomless phase of the disease that remains quiescent basically 
all through life (long-term non-progressor patients)60. On the other hand, 
expression of the Nef protein alone in transgenic mice, causes depletion of 
CD4+ T lymphocytes that resembles that observed during the course of AIDS 
pathogenesis61.  
From these studies stem the idea that we are in the presence of a factor 
essential for virus replication and for the disease progression. The structure 
of the protein, solved through crystallography in 199662 and confirmed by 
NMR 63, is well established: a central globular core with two disordered loops 
at both the N-terminal and C-terminal.  
We can mention at least three fundamental and unrelated Nef activities: 
 Modulation of T-cell activation 
 Modulation of cell surface molecule abundance 
 Modulation of retrovirus infectivity  
The effect of Nef on primary T cell activation was initially linked to a PxxP 
motif able to interact in a specific manner with the SH3 domain of two Src 
tyrosine kinase family members: Hck and Lyn64. The outcome of this 
interaction is the modulation of the TCR signalling pathway to create an 
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optimal host cell environment to allow virus replication and to avoid 
suppression of infected cells. In addition, to facilitate trafficking of the 
assembled virus-cell machinery inside the cell, Nef mediates rearrangement 
of the cytoskeleton and the actin cortex65. Cellular proteins involved in this 
process are Vav, (Rho GTPase exchange factor) and PAK (serine-threonine 
kinases) again through a PxxP/SH3 binding. In particular, it seems conceivable 
that Nef could inactivate cofillin allowing actin turn-over and induction of cell 
motility66,67  
Regulation of a number of receptor molecules exposed on the host cell 
surface is a crucial activity which the virus uses to escape the immune 
response and obtain an optimal infection level. With its ability to retrieve and 
recruit the host clathrin adaptor protein complex68, Nef is able to achieve 
both these results. Crucial in this case are the  ExxxLL69 and Yxxφ70 motifs, a 
di-acidic EE at the C-terminal loop71 and an acidic EEEE stretch at the N-
terminal72.    
Nef is well known to down regulate and promote CD4 degradation73 via the 
endosome/lysosome pathway. This activity could be important to avoid 
super-infection74. In addition, Nef prevents the formation of cytoplasmic 
CD4/gp120 complexes which interfere with the incorporation of the viral 
envelope glycoproteins in the new virus particles, as suggested by the 
evidence that the degradation of intracellular CD4 receptors results in an 
increasing number of envelope proteins available for virogenesis75,76. The 
mentioned process occurs constantly throughout disease progression. Nef 
also mediates down regulation of MHC-I during the acute infection phase77. 
The molecular basis of this mechanism is not yet well understood. One 
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possibility is that Nef recruits the AP-1 complex to address MHC-I molecules 
recycled from trans-Golgi to the endosomal compartment78. Alternatively it is 
possible to hypothesize  the involvement of the Src-family of kinases, 
mediating the discharge of MHC-I molecules from their natural localization to 
endocytic vesicles79 (Figure 1.7). 
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Figure 1.7  
Nef induces processs that contribute to HIV-1 infectivity and replication. 
www.inef.ugent.be 
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Nef  as infectivity factor  
 
The AP-2 adaptor complex along with clathrin and dynamin80 is involved in 
the Nef enhancement of HIV-1 infectivity. The first observation of this 
phenomenon came from Guatelli’s lab in 1994, which observed that optimal 
infectivity in vitro of HIV-1 requires an intact nef gene81. Then Pizzato lab 
demonstrated that the Nef requirement is restricted particularly to the 
lymphoid lineage82 (primary T cells, macrophages prior to activation). In 
addition, this effect is visible at the level of producer cells but not at the level 
of target cells83. For several years, the mechanism of the Nef effect on 
infectivity remained unknown. However another fundamental clue was 
added later: HIV-1 Nef is not the only retroviral factor with such activity. 
GlycoGag, an unrelated protein of MLV, is able to recapitulate the Nef 
phenotype82 (see below). 
With the information available at that time, two different hypothesis could 
explain the infectivity impairment observed in the Nef-defective virus (Figure 
1.8): 
 The packaging of a retroviral inhibitor into virions  
 The exclusion of a host cofactor crucial for infectivity 
 
Trying to solve the problem, at the same time and with the same purpose, my 
current research lab headed by Massimo Pizzato and the Gottlinger’s group 
started to look for a host factor able to interact with Nef, whichcould explain 
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the observed effect on virion infectivity. With two different approaches the 
two groups found the same putative candidates: SERINC5 and SERINC3. 
FIGURE 1.8   
Possible mechanisms responsible for the differential infectivity of Nef+ and Nef− 
viruses. (a), Nef− virions may acquire a defect during biogenesis which could be either the 
packaging of an inhibitor into virions (black shape), or the exclusion of a cofactor (not shown). This 
defect might then prevent the recruitment of cofactor (yellow shape) or be the target of an 
inhibitor (not shown) in target cells. (b) The effect of Nef on virus infectivity is evident when virus 
is produced from Nef-responsive cells, in which Nef regulates such inhibitor or promote virus 
assembly to subcellular locations where the defect is not acquired (b). (d) In contrast, Nef-non-
responsive producer cells generate Nef+ and Nef− viruses with similar infectivities (f). Two 
possibilities may explain this phenotype: Nef fails to protect the virus from the defect [d (1), 
Virions have suboptimal infectivity even in the presence of Nef]; alternatively, producer cells lack 
the cause of the defect or target virus assembly away from inhibitors [e,f(2), Nef- virus already has 
optimal infectivity]. 
Basmasciogullari, S., Pizzato, M., Front Microbiol. 2014; 5: 232 (2014).  
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SERINC5/3 as Nef-sensitive restriction factors  
 
HIV-1 produced in different cell lines displays different Nef dependence 
forproducing an optimal infection level. The range of the effect on infectivity 
varies between 2 and 40 fold, with all lymphoid lineages showing highest 
level of Nef requirement (Jurkat TAg, Ramos, CEM-X, Bl41), consistent with 
the lymphotropic nature of HIV-182. 
 Starting from this evidence, Rosa et al. performed RNA sequencing on 
transcriptomes of 8 high Nef-responsive cell lines, and 7 low Nef-responsive 
cell lines. This allowed to identify SERINC5 as a cellular retrovirus inhibitor 
counteracted by Nef. 
Until this discovery, that assigned SERINC5 the role of antiretroviral 
restriction factor, the protein was poorly investigated. SERINC5 is a protein 
with 9 or 10 putative transmembrane insertions (according to the splice 
isoforms)84. This factor is a member of a family which in humans includes 5 
genes, and which is highly conserved between different animal species 
(Figure 1.9). One report proposed a role of serine incorporator in cellular 
membranes, a function suggested by experiments of overexpression in yeast, 
E. coli or kidney fibroblasts from African green monkey84.  
SERINC5 expression was found to perfectly correlate with Nef requirement: 
high Nef requirement is reflected by high expression of the SERINC5 gene 
indicating anti-HIV-1 activity counteracted by Nef.  
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Figure 1.9 
Phylogenetic tree showing SERINC5 divergence between different selected animal 
species. 
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Indeed, SERINC5 and to a lesser extent SERINC3 were found to be active 
against HIV-1. 
Recruitment of the the AP-2 adaptor complex is crucial for the ability of Nef 
to counteract SERINC5. Immunofluorescence experiments showed a re-
localization of the cellular protein from the plasma membrane to the 
endosomal compartment in the presence of Nef; SERINC5 incorporation in 
the newly formed viral particles was found to prevent a productive fusion 
process85. Nef counteracts SERINC5 by excluding it from the virions (Figure 
1.10). 
Approaching the question from a different point of view, Gottlinger’s group 
performed a proteomic analysis of the virion composition in the presence 
and absence of Nef. This experimental procedure confirmed that SERINC3 
and SERINC5 are incorporated in viral particles only in Nef-depleted virus, 
consistent with what was observed by Pizzato’s group86. 
Later, an independent study analysed cellular plasma membrane proteins 
down regulated during HIV-1 infection using SILAC and the Short Time Series 
Expression Miner technique (STEM). 
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Figure 1.10  
Schematic showing the activity of SERINC5 on HIV-1. 
Rosa, A. et al. Nature 526, 212–217 (2015). 
 
. 
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Down regulation of SERINC5 and SERINC3 by Nef was observed, confirming 
the results obtained by the Pizzato and Gottlinger labs.87 
To the classical role of Nef as a modulator of proteins exposed on the viral 
particle surface, we need to add the information that even the lipid 
composition is affected by the viral protein, as reported by Fackler’s group. In 
particular, an increase of sphingomyelin and a decrease of  
phosphatidylcholine was detected in the viral envelope in the presence of 
Nef88. In contrast to previous studies89, cholesterol abundance was found 
unaffected. The impact of the effect of Nef on lipid composition of the viral 
envelope remains controversial and needs to be further investigated.  
To complete this portrait, the Nef effect on infectivity was found to be 
isolate-dependent. Nef-responsiveness was found to depend on residues in 
the V1/V2 and V3 regions of gp12086. Finally, HIV-1 pseudotyped with 
envelope proteins which lead to a pH-dependent fusion process (see for 
example VSV-G), are able to achieve optimal infection level even in the 
absence of Nef90,91. 
 
 
 
MLV glycoGag 
 
Gammaretroviruses are able to infect different vertebrates and can be found 
as exogenous or endogenous viruses.  
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Their genome is classified as “simple”, generally lacking ORFs additional to 
gag, pol and env. Since the early 1970s it is evident that gag contains a CUG 
start codon upstream to the canonical AUG, which allows the production of a 
longer Gag protein, named GlycoGag92. 
In the case of MLV, the protein is incremented by 88 amino acids at the N-
terminal and acquires a type-II transmembrane topology. Once inserted in 
the plasma membrane it is subjected to proteolytic cleavage that releases the 
C-terminal half, while the rest of the molecule remains associated to the cell 
membrane and incorporated into the virion93. GlycoGag could therefore be 
considered as an accessory protein of MLV.  
GlycoGag was found to exert a role in counteracting the anti-viral activity of 
mouse APOBEC3 (mA3). Stavrou and colleagues provided evidences that 
glycoGag prevents access of mA3to the RTC both in virions and infected cells. 
Furthermore, glycoGag was found to reduce the ability of an yet unknown 
cytosolic sensor of viral infection to respond to MLV infection; finally, 
glycoGag was found to enhance the stability of viral cores/capsids28. 
The effect of hA3G and mA3 on MLV was compared. hA3G was found to 
induce a significantly more severe inhibition compared to mA3. In contrast, 
mA3 and hA3G were found to inhibit HIV-1Vif- with a similar magnitude. MLV 
therefore appears to be partially resistant to mA3. It is possible to 
reconstruct a scenario in which  MLV exhibits partial resistance to mA3 by 
partially excluding it from nascent virions; however, incorporation of mA3 in 
MLV particles was found to occur as efficiently as for hA3G94. Therefore, the 
mechanism by which glycoGag confers MLV resistance resistance to mA3  
remains enigmatic. 
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In 2010 Pizzato reported GlycoGag as a “Nef-like” infectivity factor able to 
precisely resemble the Nef protein by rescuing infectivity of HIV-1 Nef- 
depleted virus. Similarly, both proteins are dispensable for replication in vitro 
but not in vivo95, they are sensitive to different envelope pseudotyping and 
their action is restricted mainly to lymphoid lineage producer cells. In 
addition, they share the same intracellular localization82 and the ability to 
interact with AP-296. Finally, and most importantly, they are able to similarly 
re-localize and prevent inclusion of SERINC5/3 in viral particles85,86. 
We can conclude that the effect of Nef is a fundamental property of the virus, 
genetically separated from other functions. Viruses belonging to different 
retroviral genera (lentiviruses, y-retroviruses) developed, probably through a 
mechanism of convergent evolution, two unrelated proteins to solve the 
same problem of neutralizing the inhibitory effect of SERINC proteins.  
This is the result of the host and parasite to a co-evolution over time. On one 
side restriction factors were developed by host cells to protect themselves 
from invasion, and on the other accessory proteins were evolved by viruses 
to avoid the block, and create a suitable cellular environment to achieve a 
productive infectious process. 
 APOBEC3 and tetherin evolved the ability to inhibit not only retroviruses 
from different families, but also different virus genera: APOBEC works even 
against Hepadnaviruses and tetherin shows a very broad spectrum since it is 
able to restrict Retro-, Flavi-, Filo-, Rhabdo-, Herpes-, Corona-, Paramyxo-, 
Arena-, Toga-, and Hepadnaviruses97 (Figure 1.11). 
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After the identification of SERINC5/3 as a HIV-1 restriction factors a great 
number of open questions remains and will certainly be investigated by 
research groups around the world in the future.  
With my Ph.D. thesis I will try to understand how powerful the SERINC5 
activity is and how many viruses were forced to independently evolve “Nef-
like” infectivity factors to win the battle.  
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Figure 1.11 
Antiviral restriction factors. 
Kluge, S. F. et al. Cell 163, 774-774.e1 (2015). 
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Aim of the thesis 
 
Nef, an accessory protein of HIV-1, counteracts the antiretroviral activity of 
SERINC5 by promoting its endocytosis, which results in its removal from the 
cell surface preventing its incorporation into retroviral particles. SERINC5 
inhibits not only HIV-1 but also other divergent retroviruses, such as MLV. 
MLV glycoGag can rescues the activity of Nef-defective HIV-1, further 
indicating that the two (Nef-like) retroviral factors, genetically unrelated, 
originated by convergent evolution. HIV and MLV are both lymphotropic 
retroviruses. Did other lymphotropic retroviruses evolve additional Nef-like 
infectivity factors? Do different Nef-like factors modulate retrovirus 
infectivity using the same mechanism? 
The aim of my project is to investigate the presence and understand the 
function of Nef-like factors across different retrovirus species. 
During the first few months in the lab, I have identified a factor (S2) encoded 
by EIAV (Equine infectious anemia virus) which can also functionally 
complement the infectivity of Nef-defective HIV-1. This further suggests that 
Nef-like factors are a previously over-looked class of retrovirus infectivity 
factors derived by convergent evolution. Given that the genomes of many 
retroviruses remain to be fully explored I continued to search for similar 
factors in other retroviruses (such as BIV and FIV). 
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Chapter 2: The Nef-like activity on infectivity 
across different retroviruses 
 
Introduction 
 
Nef is an accessory lentiviral protein only present in the genome of primate 
lentiviruses. GlycoGag of MLV was found to act as an infectivity factor 
functionally related to Nef, able to  rescue the infectivity of Nef-defective 
HIV-182. Translation of glycoGag in the MoMLV genome starts from a non-
canonical CUG inititation codon92. I have analyzed the sequences of different 
gammaretroviruses, both endogenous and exogenous, and found that a 
similar initiation codon, which allows translation of a glycoGag molecule, is 
present in all species considered (Figure 2.1).  
Because the GALV genome sequences available in the NCBI database lack a 
functional glycoGag ORF, we have cloned and sequenced the 5’ region of 
GALV from infected cells. We found that two nucleotides missing in the 
sequences from the database restore a functional glycoGag ORF starting from 
a CUG embedded in a perfect Kozak context. The predicted amino acid 
sequence shares similarity with glycoGag of retroviruses from non-rodent 
mammals (Figure 2.2) and provides initial evidence that the effect on 
retrovirus infectivity could be a conserved feature of glycoGag from divergent 
gammaretroviruses.  
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1 10510 20 30 40 50 60 70 80 90(1)
LGDVSEASGAIFVAQSVSENPTRLGLFGASPLTEGYVVLLG-----------G-----EGPKRSSPPSEFLFSVFRRNRAARLVCLCVVLSFVGSLLFWIVSKN-DG75 retrovirus (1)
LGDVPGTSGAIFVARPESNHPDRFGLFGAPPLEEGYVVLVG-----------D-----RGLKRFPPPSEFLLSVWNRSRAARLVCCSIVLCCLCLTVFLYLSEN-Fr MLV (1)
LGDVPGTSGAIFVARPESNHPDRFGLFGAPPLEEGYVILVG-----------D-----GRLKRFPPPSEFLLSVWSRSRAACLVCCSIVLCCLCLTVFLYLSES-Rauscher MLV (1)
LGDVPGTSGAVFVARPESKNPDRFGLFGAPPLEEGYVVLVG-----------D-----ENLKQFPPPSEFLLSVWDRSRAARLVCCSIVLCCLCLTVFLYLSEN-MoMLV (1)
-LMSGASSGTAIGAHLFGVSPEYRVLIGDEGAGP-----------------------------SKSLSEVSFSVWYRSRAARLVIFCLVASFLVPCLTFLIAETVFeLV (1)
LGDVPG-SGEDQGRLVDPSVTGRCDPISSP-----------------------------R---LVRRALNLILSLGRPRRRLWFLFVSFLESLCVTVFLSQIIN-GALV (1)
LGDVPGGIGEDQGHLVDPSAFGSGCGIPPHKEGSGCGIPPRKEGSGCGIPPRQEGSRCGIRPHP--SESLSCLWSTRSRRRFWFLFCLSLVSALVVSAIILE---Mus dunni (1)
LGDVPG-SGEDQGRLVDPSAEDHCVLIPPP----------------------------RLERRALPSDSFSCLYATRSRRRFWFLFVLFLISLCVGVSLFEIFE-Woolly Monkey SV (1)
LGDVPG-SGEDQGRLVDPTARDNSPLISQLH---------------------------CLERHTLPSDSFSCLFNIRLRRHIIFFLFISIIIIIWVVIPLFGTPRKoala retrovirus (1)
LGDAPG-GGESQGRLVVSYCRSEDRVLLLKRKLP------------------------------PPRPSDSFACLWKTRTGRVCLDLLVSVSCVFVLCVLVYSFNPERV (1)
cytoplasmic transmembrane 
R(K)XR 
motif 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 
Alignment of glycoGag amin oacid sequences from different gammaretrovirus species. 
Alignment of the cytoplasmic and transmembrane domains of glycoGag molecules derived from 
members of gammaretrovirus species with a preserved ORF. The boxed region at the N-terminal 
represents the most conserved stretch of amino acids. Highlighted in yellow is a conserved R(K)XR 
motif investigated. 
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Noteworthy, no report exists to suggest that FeLV is indeed capable of 
encoding a glycoGag molecule. From analyzing the nucleotide sequence 
available, a glycoGag potential ORF in FeLV was observed starting from a 
canonical AUG. If FeLV indeed synthesizes glycoGag, then such start codon 
must be used by the ribosome with suboptimal efficiency, to allow 
translation of Gag starting from a downstream AUG. 
All putative glycoGag molecules listed in Figure 2.1 were analyzed using the 
transmembrane topology prediction application TMHMM 2.0 
(http://www.cbs.dtu.dk/services/TMHMM-2.0), confirming the type II 
transmembrane topology in all cases. 
An alignment of the predicted glycoGag amino acid sequences derived from 
the gammaretroviruses available in the laboratory indicates that the region 
upstream of the transmembrane domain is highly variable, defining three 
distinct groups (MLV, GALV-KoRV-PERV and FeLV) which recapitulates the 
phylogenesis of the viruses analyzed.  
In this chapter, I describe the attempts to understand 1) which molecular 
features of glycoGag are crucial for the activity and 2) whether the activity on 
infectivity is a conserved attribute of the different alleles. 
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Results 
Understanding the determinants important for the 
activity of glycoGag 
 
The transmembrane region 
 
Previous results have established that most of the extracellular region of 
glycoGag is dispensable for the activity of the molecule on infectivity82. 
Accordingly, a 96aa glycoGag molecule, predicted to retain only 14 aa 
downstream of the transmembrane domain, retains considerable activity82. 
Given the presence of the transmembrane domain, it is impossible to further 
delete the molecule without imparing its proper topology. To investigate 
whether the specific transmembrane domain (TM) sequence of glycoGag is 
important, I replaced the 23aa contained in the predicted TM helix of 
glycoGag with those derived from influenza neuraminidase (NA), a 
heterologous type II transmembrane protein. The construct containing such 
substitution retained most of the ability to rescue HIV-1 infectivity (Figure 
2.3.), indicating that a glycoGag-specific transmembrane sequence is not 
absolutely required for the activity. 
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Figure 2.3                                                                                                                                             
The glycoGag-specific transmembrane sequence is not required for its activity on 
infectivity.                     
Infectivity of Nef-defective HIV-1 alone or in the presence of HA-glycoGag (HA-gg) wt or HA-
glycoGag NA (HA-gg NA) obtained by electroporation of JTAg used as producer cells. Nef-negative 
HIV-1 was obtained with a two-vector system composed by a NL4-3-derived plasmid deficient for 
env and nef and complemented with pbj5 expressing HIV-1HXB2env. 4:4:1 ratio between viral 
backbone, HA-glycoGag/HA-glycoGag NA or empty vector and env was used. Supernatant of 
producer cells was collected 48h post-transfection and used to infect TZM-GFP reporter cells, as 
described in materials and methods and analysed through automatized microscopy. Infectivity 
values are the average of 4 independent transfections (biological quadruplicates). Error bars 
represent standard deviation of the mean. Statistical significance was calculated by unpaired two-
tailed t-test (* P<0.05, ** p<0.01, *** p<0.001). Representative experiment out of 3 repetitions. 
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The N-terminal region 
  
The alignment of glycoGag molecules reveals that the region of glycoGag 
upstream the gag AUG is relatively poorly conserved. However, the first 10 
aa appear to be highly conserved (with the only exception of FeLV). To test 
whether the N-terminal of the protein plays an important role and verify 
whether the first 10aa of MoMLV glycoGag are crucial for the activity on 
infectivity, two increasing N-terminal deletions (23 aa and 56 aa) were 
introduced in the context of a minimal glycoGag molecule, which lacks most 
of the extracellular region (gg189). To facilitate detection in Western blotting, 
an HA tag was fused at the N-terminal, since it was previously found to be 
compatibile with the activity of MoMLV glycoGag 82. 
The ability of these deletion mutants to rescue the infectivity of HIV-1 was 
tested by expressing the mutated constructs together with a two-part HIV-1 
NL4-3 vector (env-defective HIV-1NL4-3 complemented with env derived from 
HIV-1HXB2) in JTAg cells. JTAg cells were chosen because among the cell lines 
that have been tested in our laboratory, they are those which depend most 
on Nef for the production of fully infectious HIV-1. Viruses obtained were 
used to infect a TZM-bl reporter cell line, engineered to contain a HIV-1 LTR-
driven cassette for Tat-dependent expression of nlsZsGreen (TZM-GFP), 
which allows scoring infection events using an automated fluorescent 
microscope for High Content Screening (Operetta PE). After normalization of 
progeny virus based on the RT-activity of the inocula using SG-PERT, virus 
infectivity was calculated. Results show that deletion of the first 26 aa do not 
affect the ability of the molecule to rescue HIV-1, indicating that the most 
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conserved N-terminal region (the first 10aa) is not required for the activity. 
Larger deletions totally impaired glycoGag function. Western blotting 
analyses revealed that glycoGag expression was majorly and increasingly 
affected by the extent of the deletion introduced. Since deletions spanning 
over the first N-terminal 26aa are crucial for the correct expression, the role 
of the downstream aa remains to be established (Figure 2.4). 
 
The potential presence of sorting signals 
 
One additional conserved feature which was observed among glycoGag 
molecules from different retrovirus species is a R(K)XR motif adjacent to the 
transmembrane helix. 
A similar motif of basic amino acids located near the transmembrane domain 
resembles the stop transfer signal for translocation of type-II proteins 
through the lipid bi-layer98. However, I have tested an exhaustive dataset of 
Type II transmembrane proteins 
(http://ccb.imb.uq.edu.au/golgi/documents/Training_Set.html) and rarely 
found an R(K)XR motif in close proximity of the transmembrane domain. 
Considering the high variability of the glycoGag region surrounding this motif, 
we think that the conservation of the R(K)XR sequence could have another 
functional meaning. Interestingly, an RXR motif within the cytoplasmic tail of 
type II proteins is known to function as an endoplasmic reticulum retention 
signal99–101. Despite some evidence indicating that RXR signals are 
preferentially found distantly from the membrane98, given the perinuclear  
53 
 
Figure 2.4  
The N-terminal 26 aa of MoMLV glycoGag are not required for activity.  
Schematic (a) and activity on infectivity (b) of N-terminal deletions introduced. 
(c) Western blot analysis of glycoGag deletion mutants expression in corresponding cell 
lysates. (d), schematic illustrating the minimal glycoGag region required for activity on 
infectivity. 
Nef-negative HIV-1 was obtained with a two-vector system composed by a NL4-3 derived 
plasmid deficient for env and nef and complemented with pbj5 expressing HIV-1HXB2env. 4:4:1 
ratio between viral backbone, HA-glycoGag wt/HA-glycoGag 189 mutant/ HA-glycoGag 26-
189 mutant/HA-glycoGag 53-189 mutant or empty vector and env was used. Supernatant of 
producer cells was collected 48h post-transfection and used to infect TZM-GFP reporter cells, 
as described in materials and methods and analysed through automatized microscopy. 
 Corresponding JTAg cell lysates are resolved by SDS-PAGE and analysed by WB. 
Infectivity values represent the average of 4 independent transfections (biological 
quadruplicates). Error bars represent standard deviation of the mean. Statistical significance 
was calculated by unpaired two-tailed test (* P<0.05, ** p<0.01, *** p<0.001). 
Representative experiment out of 3 repetitions. 
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Figure 2.5 
The RXR motif of MoMLV glycoGag is not required for activity. 
(a) Immunofluorescence microscopy on COS-7 cells transfected to allow the expression of 
HA-glycoGag wt or HA-glycoGag RR61,63AA. 
(b)  Activity on infectivity of the indicated glycoGag constructs.                                                                                     
Nef-negative HIV-1 was obtained with a two-vector system composed by a NL4-3 derived 
plasmid deficient for env and nef and complemented with pbj5 expressing HIV-1HXB2env. 
4:4:1 ratio between viral backbone, HA-glycoGag wt/HA-glicoGag RR61,63AA or empty 
vector and env was used. Supernatant of JTAG producer cells was collected 48h post-
transfection and used to infect TZM-GFP reporter cells, as described in materials and 
methods and analysed through automatized microscopy. Infectivity values represent the 
average of 4 independent transfections (biological quadruplicates). Error bars represent 
standard deviation of the mean. Statistical significance was calculated by unpaired two-tailed 
test (* P<0.05, ** p<0.01, *** p<0.001). Representative experiment out of 3 repetitions. 
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localization of glycoGag observed in immunofluorescence microscopy, I 
tested whether the R(K)XR sequence plays a role in subcellular targeting of 
glycoGag and is important for its activity. 
The RXR motif of gg189 (derived from MoMLV) was converted into AXA using 
site-directed mutagenesis. The effect of the mutation was tested on the 
subcellular localization of the protein and its ability to rescue Nef-defective 
HIV-1 infectivity. As shown in Figure 2.5 a, the intracellular localization of the 
AXA variant in transfected COS-7 cells was identical to that of the wt protein, 
denoting a strong accumulation in perinuclear compartments. Similarly, the 
mutant protein could rescue HIV-1 infectivity as much as the wt protein 
(Figure 2.5 b). The RXR motif, therefore, although highly conserved, plays no 
role on glycoGag function. 
 
The importance of endocytosis for glycoGag function 
 
The activity of Nef on infectivity is known to depend on the ability of the  
protein to interact with important players of the biogenesis of endocytic 
vesicles such as AP2 and dynamin 2. In addition, it has been demonstrated 
that a functional endocytic machinery is required for the effect on 
infectivity80. It has not been so far demonstrated that this was also the case 
for glycoGag. 
To investigate the role of endocytosis in glycoGag activity, transdominant-
negative inhibitors of clathrin-mediated vesicle biogenesis were expressed in 
virus producing cells and their effect on the ability of glycoGag to increase 
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Nef-defective HIV-1 infectivity was evaluated. Both, dominant-negative 
dynamin 2 and a C-terminal fragment of the clathrin adaptor protein  AP180 
were used, since they were previously found to efficiently inhibit Nef80. 
Similarly, both inhibitors strongly impaired the ability of glycoGag to alter 
HIV-1 infectivity, suggesting that, like in the case of Nef, clathrin-mediated 
endocytosis plays a crucial role (Figure 2.6). This indicates that, similarly to 
Nef, glycoGag could recruit components of the endocytic machinery. 
Accordingly, while we were attempting to identify intracellular sorting signals 
within the aa sequence of glycoGag, the Gottlinger’s laboratory reported that 
a YxxL motif in MLV glycoGag, predicted to recruit AP-2, is crucial for the 
activity on infectivity96. Interestingly, such motif is not conserved among 
glycoGag alleles from different retroviruses, raising the possibility that also 
the activity on infectivity may not be conserved. 
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Figure 2.6 
The importance of endocytosis for glycoGag function. 
Expression of dominant negative dynamin 2 (DNM2/K44A) and a transdominant negative 
fragment of AP-180 (AP180 C) in virus producing cells inhibits the activity of MoMLV glycoGag on 
the infectivity of Nef-defective HIV-1. 
Nef-negative HIV-1 was obtained with a two-vector system composed by a NL4-3 derived plasmid 
deficient for env and nef and complemented with pbj5 expressing HIV-1HXB2 env. 4:4:1 ratio 
between viral backbone, HA-glycoGag or empty vector and env was used. 1:1.5 ratio between 
glycoGag and each endocytosis inhibitor tested separately was used. 
 Supernatant of JTAG producer cells was collected 48h post-transfection and used to infect TZM-
GFP reporter cells, as described in materials and methods, and analysed through automatized 
microscopy. Infectivity values are average of 4 independent transfections (biological 
quadruplicates). Error bars represent standard deviation of the mean. Statistical significance was 
calculated by unpaired two-tailed t-test (* P<0.05, ** p<0.01, *** p<0.001). Shown is a 
representative experiment out of 3 repetitions. 
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The activity of glycoGag alleles from different 
gammaretroviruses on HIV-1 infectivity is not 
conserved 
 
The ability of FeLV to produce a glycoGag molecule has never been 
established. We therefore started with testing whether the FeLV genome is 
capable of providing a Nef-like activity on HIV-1 infectivity. We produced HIV-
1 in JTAg cells in the presence or absence of the full FeLV-A provirus. As 
expected, the absence of Nef introduced a 7-fold defect in HIV-1 infectivity. 
Co-transfection with a FeLV-A genome resulted in a 3-fold rescue of the 
infectivity of Nef-defective HIV-1 (Figure 2.7). While this increase of 
infectivity appears to be partial, this result was reproducible in several 
experiments, suggesting that the FeLV-A genome could encode a Nef-like 
infectivity factor. 
Indication that GALV encodes for a Nef-like factor came previously with the 
observation that HIV-1 derived from the lymphoid cell line A3.01/F7102, which 
was found to be contaminated with GALV-X, does not require Nef for 
infectivity. In contrast, HIV-1 derived from the parental, non-contaminated, 
A3.01 cells depends on Nef for optimal infectivity82. 
In order to test and compare the activity of glycoGag alleles isolated from 
different retrovirus species, we isolated and cloned each sequence in a pbj5 
expression vector, under the control of the same SRalpha promoter. 
GlycoGag sequences were cloned from FeLV-A, KoRV, GALV-X and PERV-A. 
The glycoGag from GALV was derived from viral RNA isolated from retrovirus 
particles pelleted from the supernatant of A3.01/F7 cells. 
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Figure 2.7 
FeLV-A activity on infectivity. 
Infectivity of HIV-1 wt or Nef-negative produced by electroporation of JTAg cells, in the presence 
and in the absence of FeLV-A molecular clone. 
 HIV-1 wt or Nef-negative is obtained with a two-vector system composed by a NL4-3 derived 
plasmid deficient for env and for env and nef and complemented with pbj5 expressing HIV-
1HXB2env. 4:8:1 ratio between viral backbone, FeLV molecular clone or empty vector and env was 
used. Supernatant of producer cells was collected 48h post-transfection and used to infect TZM-
GFP reporter cells, as described in materials and methods and analysed through automatized 
microscopy.  
Infectivity values are average of 4 independent transfections (biological quadruplicates). Error 
bars represent standard deviation of the mean. Statistical significance was calculated by unpaired 
two-tailed test (* P<0.05, ** p<0.01, *** p<0.001). Representative experiment out of 3 
repetitions. 
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Since it was previously demonstrated that the activity on infectivity maps 
within the intracellular domain of glycoGag, only the 5’ 288 nt were cloned 
and used to replace the homologous region within MoMLV HA-gg196, up to a 
stretch of highly conserved amino acids, which include a AflII restriction site 
in the MoMLV genetic sequence. (See materials and methods section for 
cloning strategy) 
 To allow detection in Western blot assays, all genes were cloned by fusing an 
HA-tag at the N-terminal, which was already shown to be compatible with 
the activity of MoMLV glycoGag82. Accordingly, after transfecting JTAG cells 
with the constructs encoding the different glycoGag alleles, all molecules 
could be detected at the expected molecular size. 
Each construct expressing glycoGag was co-transfected, along with Nef-
defective HIV-1 provirus constructs, into JTAg cells. (Figure 2.8). Infectivity of 
progeny viruses measured on TZM-GFP cells revealed that glycoGag from 
GALV can partially rescue the infectivity of HIV-1, which could be fully 
rescued by MoMLV glycoGag. This confirms the indication originated from 
A3.01 cells, that GALV has the ability to repair the infectivity of Nef-defective 
HIV-1. In contrast, the molecules cloned from PERV, KoRV and FeLV-A did not 
affect HIV-1 infectivity, suggesting that, at least in this experimental setting, 
the intracellular portion of glycoGag derived from these retroviruses cannot 
replace the activity of Nef. These results indicate that the ability to increase 
retrovirus infectivity is variable and might not represent a conserved property 
of gammaretrovirus glycoGag alleles. Unexpectedly, expression of FeLV-
derived HA-glycoGag did not confirm the effect on HIV infectivity obtained by 
transfecting the full-length retroviral molecular clone. Further experiments 
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would be at this stage required to understand whether this is due to 
suboptimal expression levels of the HA-glycoGag molecule, or to a 
requirement FeLV glycoGag sequences at the C-terminus of the molecule.  
 
The ability of glycoGag alleles to target SERINC5 
 
While I was carrying out this investigation on glycoGag alleles, a parallel 
project in the lab identified a host transmembrane protein (SERINC5) which 
explains the effect of Nef and glycoGag on retrovirus infectivity. SERINC5 acts 
as an inhibitor of the retrovirus particle and is counteracted by both 
retrovirus molecules. As observed by immunofluorescence microscopy, Nef 
and glycoGag target SERINC5 and downregulate its surface expression level 
by promoting its accumulation into a late endosomal compartment. We 
investigated whether the variable activity of glycoGag molecules observed on 
virus infectivity correlates with a variability on their ability to promote 
endocytosis and intracellular accumulation of SERINC5. 
To assess the ability of glycoGag molecules to target SERINC5 we transfected 
JTAg cells with constructs expressing HA-tagged gg189 genes along with a 
plasmid expressing SERINC5-GFP. As revealed by HA immunostaining, 
similarly to MoMLV glycoGag, despite the absence of a reproducible effect on 
HIV-1, FeLV-A, PERV and KoRV-derived glycoGag could to various extent 
produce a noticeable SERINC5 intracellular accumulation. This indicates that 
all molecules are capable of targeting the host factor, but this is not sufficient 
to rescue the infectivity of HIV-1(Figure 2.9). 
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Figure 2.8 
Overexpression of glygoGag (gg) from different species do not rescue infectivity of HIV-
1 Nef defective virus. 
Infectivity (a, c, e) and expression levels in corresponding cell lysates (b, d, f) of HA-FeLV-A   , HA-
KORV, HA-PERV and HA-GALV gg transfected in the presence of Nef-negative HIV-1 in JTAg 
producer cells. 
Nef-negative HIV-1 was obtained with a two-vector system composed by a NL4-3 derived plasmid 
deficient for env and nef and complemented with pbj5 expressing HIV-1HXB2env. 4:4:1 ratio 
between viral backbone, each glycoGag or empty vector and env was used. Supernatant of 
producer cells was collected 48h post-transfection and used to infect TZM-GFP reporter cells, as 
described in materials and methods and analysed through automatized microscopy.  
Corresponding JTAg cell lysates are resolved by SDS-PAGE and analysed by WB.  
Infectivity values are average of 4 independent transfections (biological quadruplicates). Error 
bars represent standard deviation of the mean. Statistical significance was calculated by unpaired 
two-tailed test (* P<0.05, ** p<0.01, *** p<0.001). Representative experiment out of 3 
repetitions. 
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Figure 2.9 
The ability of glycoGag alleles to target SERINC5. 
Confocal microscopy of JTAg cells transfected to express SERINC GFP alone (a),  or   along with  HA-
glycoGag molecules derived from PERV (b), FeLV (c), KoRV (d) and MLV (e). 
Representative experiment out of 3 repetitions. 
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Discovery and characterization of novel Nef-like 
infectivity factors 
 
Research in our lab has demonstrated that Nef from primate lentiviruses and 
glycoGag from gammaretroviruses have independently evolved functionally 
related activities which modulate retrovirus infectivity. We investigated 
whether retroviruses other than primate lentiviruses and gammaretroviruses 
have evolved Nef-like factors. We restricted our investigation to FIV, WDSV, 
BIV and EIAV, because their genome encode for yet not fully functionally 
characterized accessory proteins. 
1) Feline Immunodeficiency Virus causes a pathology which is very similar to 
human AIDS and, like HIV, is a T-cell tropic lentivirus. We focused our 
attention to the accessory protein ORF-A which was reported to be required 
for optimal intrinsic infectivity of FIV produced from T-lymphocytes103 and, 
like Nef, promotes the downregulation of the receptor (CD134)104. 
2) The activity of both glycoGag (a transmembrane protein) and Nef 
(myristoylated) requires the ability of these accessory proteins to associate 
with the cell membrane. We searched, among different retroviruses, for 
those capable of encoding transmembrane accessory proteins. Bovine 
immunodeficiency virus, another lentivirus, expresses a transmembrane 
protein (TMX) from an ORF located, like nef in HIV-1, at the 3’ of the genome. 
Since TMX remains currently orphan of a molecular function, we decided to 
investigate whether it could have evolved a Nef-like function. 
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3) Another common feature between Nef and glycoGag is the presence of 
motifs (E/DxxxLL and YxxLL respectively) predicted to interact with AP2. 
While searching from retrovirus factors which contain putative AP2 binding 
motifs, we noticed that both an E/DxxxLL and YxxLL motifs are present in the 
accessory protein ORF2 from Walleye Dermal Sarcoma, indicating its possible 
role in modulating endocytosis. 
4) Finally, our attention was focused on Equine infectious anemia virus, which 
expresses a small accessory protein (S2) required for disease progression in 
vivo, which, like Nef, also contains a ExxxL motif. 
To investigate whether Orf-A is a Nef-like factor, the gene from the Petaluma 
isolate fused to a HA-Tag at its C-terminal was overexpressed in JTAg cells 
producing Nef-defective HIV-1. We observed no effect on HIV-1 infectivity in 
conditions where Nef caused a 10-fold increase of infectivity. However, with 
immunoblotting with anti-HA, no signal was visible from cell lysates (not 
shown). Given the low molecular weight of ORF-A (6KDa), detection could be 
difficult and might require maximization of expression. We therefore 
synthesized an ORF optimized for the human codon usage. Because a tag 
fused to such a small protein could have deleterious effects, both an 
untagged and a FLAG-tagged versions were generated. While the tagged 
protein could be readily visualized in the lysates of virus producing cells, 
again no effect was observed on HIV-1 infectivity (Figure 2.10) in the absence 
of Nef. Similarly, the untagged protein did not alter HIV-1 (not shown). 
Genes expressing TMX from BIV (accession number: AAA64394.1) and ORF-2 
from WDSV (accession number: NP_045940) were also synthesized with 
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optimized human codon usage and with a HA tag fused at the C- terminal, 
based on the sequence of reference genomes. Both proteins were readily 
visible by immunoblotting in the lysates of HIV-1 producing cells. However no 
effect could be observed on HIV-1 infectivity (Figure 2.10). 
These results indicated that, in these experimental conditions, ORF-A, TMX 
and ORF-2 do not function as a Nef-like protein for HIV-1 infectivity. 
In contrast, the infectivity of Nef-defective HIV-1 was rescued by expression 
of the accessory protein S2 from the P19/Wenv 16 EIAV isolate.  
The molecular and functional characterization of S2 is described in the next 
chapter.    
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Figure 2.10 
WEHV-ORF2, FIV-ORF-A and BIV-TMX don’t show significant Nef-like activity. 
a) Infectivity data  of Nef clade C used as a positive control, ORF2, ORF-A and TMX 
transfected in the presence of HIV-1 Nef deficient virus in JTAg producer cells. 
b,c)  Expression levels in corresponding cell lysates.   
 
Nef-negative HIV-1 was obtained with a two-vector system composed by a NL4-3 derived 
plasmid deficient for env and nef and complemented with pbj5 expressing HIV-1HXB2env. 4:4:1 
ratio between viral backbone, Nef c /ORF2/ORF-A/TMX or empty vector and env was used. 
Supernatant of producer cells was collected 48h post-transfection and used to infect TZM-GFP 
reporter cells, as described in materials and methods and analysed through automatized 
microscopy. Corresponding JTAg cell lysates are resolved by SDS-PAGE and analysed by WB. 
Infectivity values are average of 4 independent transfections (biological quadruplicates). Error 
bars represent standard deviation of the mean. Statistical significance was calculated by 
unpaired two-tailed test (* P<0.05, ** p<0.01, *** p<0.001). Representative experiment out of 3 
repetitions. 
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Discussion 
 
An ORF encoding glycoGag is present in most gammaretrovirus genomes that 
we could retrieve in the Genbank database. The sequence of the predicted 
cytoplasmic and transmembrane domains appears to be poorly conserved 
among different retroviruses. Initially, we assumed that all glycoGag alleles 
would be active on retrovirus infectivity. We therefore studied whether the 
same features that are most common between the alleles are also those 
required for the activity. Surprisingly, the two most conserved features, i.e. 
the highly conserved N-terminal region and a R(K)xR motif present in all 
glycoGag alleles, are not required. We therefore investigated whether indeed 
all glycoGag molecules function as Nef-like infectivity factors on HIV-1. Our 
results suggest that the activity on HIV-1 infectivity might not be a conserved 
feature of glycoGag. However, further studies should address this possibility. 
While all our investigations with glycoGag alleles isolated from different 
gammaretroviruses species were performed using HIV-1 as a model, it would 
be now essential to test their activity on the infectivity of the retrovirus from 
which each molecule was derived. However, technical difficulties make this 
approach challenging. First, an infectivity assay for all different 
gammaretroviruses considered here is not readily available, making difficult 
to generate the molecular tools required to assess the effect of glycoGag on 
infectivity. Second, the sequence encoding glycoGag overlaps with the 
packaging signal of gammaretroviruses. This implies that the overexpression 
of glycoGag in trans in a system producing a gammaretrovirus vector would 
negatively impact on the infectivity of the retroviral particles because the 
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glycoGag RNA sequence overexpressed would likely compete with the 
packaging signal of the retroviral genome, excluding the latter from virions. 
The effect of each glycoGag would therefore have to be studied by mutating 
its sequence in cis within each retrovirus genome. 
Our laboratory has established that Nef and glycoGag act by counteracting 
the host factor SERINC5. We have performed all our experiment using human 
cell lines as producer cells, therefore testing only the ability of the different 
glycoGag molecules to counteract the human host factor. A possibility 
remains that retroviruses which evolved in different animal species adapted 
to antagonize SERINC5 in a species-specific manner. While our lab has 
established that MoMLV glycoGag can efficiently counteract human SERINC5, 
it remains possible that other glycoGag, such as those from PERV and KoRV, 
are active against the porcine and koala host factors rather than the human 
counterpart. To this end, SERINC5 from all these different species should be 
cloned and expressed in order to verify whether such species-specificity 
exists. The same considerations should be extended to my attempt to identify 
Nef-like factors in the genome of other retroviruses (FIV, WDSV and BIV), 
which could have evolved host species-specificity against SERINC5. 
While this research was in progress, the Gottlinger group identified a YxxL 
motif, predicted to recruit AP2, as essential for the activity. This is consistent 
with our result which shows that clathrin-mediated endocytosis is also 
required for the effect on infectivity. Accordingly, we also observed the 
presence of a YxxL in FeLV glycoGag, and a ExxxLL motif in the PERV 
molecule. It is therefore possible that the ability to interact with AP2 is 
required but not sufficient for the glycoGag effect on infectivity. In line with 
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this hypothesis, we observed that, irrespectively of the effect documented on 
HIV-1 infectivity, all glycoGag molecules indeed can cause the intracellular 
accumulation of SERINC5, suggesting that the ability to perturb intracellular 
vesicle trafficking is present. Interestingly, our laboratory identified a nef 
allele, from a subtype H isolate, which, like the glycoGags described here, 
does not affect HIV-1 infectivity, despite maintaining the ability to promote 
intracellular accumulation of SERINC5 (unpublished). Altogether, this is 
reminiscent of the activity of Vpu against the restriction factor BST2105. While 
Vpu was found to re-route BST2 from the plasma membrane via an endocytic 
pathway, naturally occurring alleles were identified which fail to counteract 
the antiviral activity of BST2 despite retaining the ability to promote BST2 
dowregulation. Like in the case of Vpu, therefore, the mechanism by which 
Nef and glycoGag counteract SERINC5 remains to be fully established. 
The gammaretroviruses analyzed in this thesis are both exogenous and 
endogenous retroviruses. It is interesting to notice that, while an effect of 
glycoGag from exogenous retroviruses (MoMLV, FeLV-A and GALV) on HIV-1 
infectivity was observed (though weaker with FeLV and GALV), the glycoGag 
molecules from the PERV and from KoRV, which is currently undergoing the 
process of endogenization, display no activity on HIV-1 infectivity, It is 
therefore tempting to speculate that the process of endogenization might 
require the loss of glycoGag ability to counteract SERINC5. To this end it will 
be interesting to analyze glycoGag alleles from more exogenous and 
endogenous retroviruses, to verify this hypothesis. 
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Chapter 3: The Equine infectious anemia virus 
S2 accessory protein is a factor which 
promotes retrovirus infectivity 
 
Introduction 
 
EIAV is a lentivirus with macrophage-tropism causing a chronic disease in 
equids. The disease associated with EIAV was identified in 1843 and was the 
first pathology demonstrated to be caused by an infectious agent. It was also 
the first disease proven to be caused by a virus (“a filterable” agent) in 1904. 
However, the identification and characterization of the etiological agent 
causing such disease occurred only in the 1970.  
EIAV infection occurs through blood-feeding horse flies and results in three 
clinical stages: acute, chronic and inapparent. The acute and chronic stages 
are symptomatic and characterized by fever, anemia, thrombocytopenia, 
edema and lethargy. One year after infection, the animals typically progress 
to a life-long inapparent stage, displaying non recognizable clinical signs of 
disease. During this period of steady state viral replication, monocyte-rich 
tissues become a reservoir of infection that could be re-activated by both 
immune suppression and stress conditions. During this phase of the infection, 
the animals are carriers and transmit the virus to other animals106. 
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During the last twenty years, the characterization of cellular receptors used 
by retroviruses has been well established for different lymphotropic 
lentiviruses such as human, simian and feline immunodeficiency viruses. 
Their study helped to underline a common theme for entry of these viruses 
that share the peculiarity to bind sequentially two cellular coreceptors. In 
contrast EIAV lentiviruses use a single receptor, ELR1, belonging to the family 
of TNF receptor proteins. This family of receptors mediate the infectious 
process for B, D and E  avian  leukosis virus subtypes  and  for feline leukimia 
virus as well107.  
EIAV is a complex retrovirus, with the genes tat, rev and S2 expressed in 
addition to gag, pol and env. (Figure 3.1a). While the function of all EIAV 
genes is relatively well understood and recapitulates the functions already 
discussed for other retroviruses of the Retroviridae family, the role of S2 
remains enigmatic.  
S2 is a small (7KDa), poorly studied accessory factor. Neither its position in 
the genome nor its amino acid sequence were found to be similar to those of 
other viral or cellular proteins. The information available can be summarized 
as follows: 
 S2 is not required for optimal virus release, as in vitro studies have shown 
that EIAV lacking S2 is produced as efficiently as wild-type EIAV108. 
 No evident defect could be observed in the ability of EIAV to infect target 
cells, including monocytes, in the absence of S2.109 
The pathology associated with S2-defective viruses is less severe than that 
caused by the wt virus. The removal of S2 from the EIAV genome was found 
to associate with lower viral load in animals, and with absence of clinical 
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symptoms110. Given the crucial pathogenic role of S2, a S2-defective EIAV 
vaccine was also studied, as it was found to confer 100% protection111. 
This observation prompted us to investigate the potential of S2 as a Nef-like 
infectivity factor. The structure of S2 has never been investigated. 
Computational studies, however, predict a putative SH3-binding motif and a 
controversial putative myristoylation signal. Accordingly, myristoylation of S2 
was suggested, but not experimentally proven, by a report112 (Figure 3.1b). 
Interestingly, we also observed that a ExxxLL motif is present in S2 and could 
be predicted to function as the binding site for AP2. 
As mentioned in the previous chapter, during a preliminary screening to 
investigate the presence of Nef-like infectivity factors in different retrovirus 
species, S2 was found capable of increasing the infectivity of Nef-defective 
HIV-1. Here I therefore describe an in depth functional and molecular 
characterization of EIAV S2. 
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Figure 3.1 
Genome of Equine infectious anemia virus and the S2 amino acid sequence. 
 a) Location of all genes is indicated. LTR: long terminal repeat; tat: transactivator; pol: polimerase; 
rev: regulator of virion expression; env: envelope.  b) S2 amino acid sequence and predicted 
functional motifs.   
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Results  
S2 is an infectivity factor for the EIAV retrovirus 
 
S2 rescues the infectivity of Nef-defective HIV-1 
 
To investigate the putative role of S2 in the enhancement of viral infectivity, 
we tested whether S2 is able to rescue the defective infectivity of HIV-1 in the 
absence of Nef. JTag cells where used as producer cells in these experiments, 
because they are highly Nef responsive for the effect on HIV-1 infectivity. 
Virus capable of only one round of replication (wt and Nef-defective HIV-1) 
was produced by transfecting JTAg cells, with env-defective molecular clones 
supplemented with a plasmid encoding HIV-1 Env and a vector expressing S2, 
derived from the p19/wenv 16 EIAV strain. While the absence of Nef caused 
an 80% reduction of virus infectivity, S2 expressed in producer cells rescued 
such defect (Figure 3.2). Expression of S2 did not alter significantly the 
amount of HIV-1 produced (not shown) indicating that the EIAV protein 
affects exclusively the intrinsic infectivity of virus particles. In contrast, no 
significant enhancement was documented on the infectivity of HIV-1 in the 
presence of Nef, indicating that there is no synergistic effect between Nef 
and S2 and suggesting that the two proteins complement the same defect. 
Having tested the activity of S2 derived from the highly virulent p19/wenv 16 
strain, we tested whether the ability to affect HIV-1 infectivity was shared 
with S2 from a different EIAV strain. We therefore synthesized S2 based on 
the sequence from the Wyoming EIAV strain, which differs for 2 aa. 
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 Such S2 alleles were found to exert a similar activity on the infectivity of Nef-
defective HIV-1 produced in Jurkat TAg cells. (Figure3.3) 
Altogether, these results suggest that S2 functions as a Nef-like molecule. 
 
The Nef effect on HIV-1 is strongly dependent on the producer cells type82. 
We therefore investigated whether the same is true for the activity of S2. 
We used CEMX-174, which is a cell line which is not responsive to Nef. When 
HIV-1 was produced in this cell line in the presence of a vector expressing S2, 
the EIAV protein did not affect virus infectivity, confirming the Nef-like 
character of its activity (Figure 3.4).  
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Figure 3.2 
EIAV S2 rescues the infectivity of Nef-negative HIV-1 virus. 
Relative infectivity (% of the control Nef+ sample) of HIV-1  wt or Nef-negative, obtained by  JTAg 
electroporation in the presence or in the absence of EIAV S2 provided in trans.  
HIV-1 wt or Nef-negative was obtained with a two-vector system composed by a NL4-3 derived 
plasmid deficient for env and for env and nef and complemented with pbj5 expressing HIV-
1HXB2env. 4:4:1 ratio between viral backbone, S2 or empty vector and env was used. Supernatant 
of producer cells was collected 48h post-transfection and used to infect TZM-GFP reporter cells, 
as described in materials and methods and analysed through automatized microscopy.  
Infectivity values are average of 4 independent transfections (biological quadruplicates). Error 
bars represent standard deviation of the mean. Statistical significance was calculated by 
unpaired two-tailed test (* P<0.05, ** p<0.01, *** p<0.001). Representative experiment out of 3 
repetitions. 
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Figure 3.3 
EIAV S2 from the Wyoming strain rescues infectivity of HIV-1nef- virus. 
a) Schematic representation of S2 Wyoming amino acid sequence.  
b) Infectivity of Nef-negative HIV-1, obtained by JTAg electroporation in the presence or in the 
absence of p19/wenv 16 EIAV S2-HA or Wyoming EIAV S2-HA provided in trans.  
 
Nef-negative HIV-1 was obtained with a two-vector system composed by a NL4-3 derived plasmid 
deficient for env and nef and complemented with pbj5 expressing HIV-1HXB2env. 4:4:1 ratio 
between viral backbone, p19/wenv 16 EIAV S2-HA / Wyoming EIAV S2-HA or empty vector and 
env was used. Supernatant of producer cells was collected 48h post-transfection and used to 
infect TZM-GFP reporter cells, as described in materials and methods and analysed through 
automatized microscopy. Infectivity values are average of 4 independent transfections (biological 
quadruplicates). Error bars represent standard deviation of the mean. Statistical significance was 
calculated by unpaired two-tailed test (* P<0.05, ** p<0.01, *** p<0.001). Representative 
experiment out of 3 repetitions.  
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Figure 3.4 
S2 does not affect the infectivity of HIV-1 produced in CEMX174 cells. 
Relative infectivity (% of the control Nef+ sample) of HIV-1 wt or Nef-negative, obtained by 
electroporation of Nef non responsive CEMX174 cells line, in the presence or in the absence of EIAV 
S2 provided in trans.  
HIV-1 wt or Nef-negative was obtained with a two-vector system composed by a NL4-3 derived 
plasmid deficient for env and for env and nef and complemented with pbj5 expressing HIV-1HXB2env. 
4:4:1 ratio between viral backbone, S2 or empty vector and env was used. Supernatant of producer 
cells was collected 48h post-transfection and used to infect TZM-GFP reporter cells, as described in 
materials and methods and analysed through automatized microscopy.  
Infectivity values are average of 4 independent transfections (biological quadruplicates). Error bars 
represent standard deviation of the mean. Statistical significance was calculated by unpaired two-
tailed test (* P<0.05, ** p<0.01, *** p<0.001). Representative experiment out of 3 repetitions. 
. 
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S2 does not affect MLV infectivity 
 
As HIV requires Nef for infectivity, MLV requires glycoGag82. We therefore 
tested whether S2 can replace the activity of glycoGag for MLV infectivity. A 
MoMLV which expresses GFP in place of env was pseudotyped with the 
envelope glycoprotein derived from the xenotropic NZB isolate by 
transfecting JTAg cells. Wt or glycoGag-negative virus was produced in the 
presence or absence of the S2-expressing construct. The level of infection of 
TE671 target cells was scored in flow cytometry. As shown in Figure 3.5, the 
absence of glycoGag introduces a 12-fold defect on infectivity. Co-
transfection of the S2 expressing plasmid, however, did not rescue virus 
infectivity, suggesting that S2 does not functionally replace glycoGag (Figure 
3.5). This is reminiscent of a result reported previously, which indicates that 
while glycoGag can rescue the infectivity of Nef-defective HIV-1, Nef cannot 
rescue the infectivity of the glycoGag-defective MLV82. 
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glycoGag-negative      
MLV  
       MLV wt glycoGag-negative        
           MLV  
Figure 3.5 
EIAV S2 does not rescue the infectivity of glycoGag-negative MLV. 
Relative infectivity of MLV wt or glycoGag-negative viruses, produced in JTAg cells in the presence or in the absence 
of EIAV S2 provided in trans. 
MLV wt or glycoGag-negative MLV are complemented with and MLV-NZB-9-1 envelope. 4:4:1 ratio between viral 
backbone, S2 or empty vector and env was used. Supernatant of producer cells was collected 48h post-transfection 
and used to infect TE671 cells as described in materials and methods and analysed through FACS.  
Infectivity values are average of 4 independent transfections (biological quadruplicates). Error bars represent 
standard deviation of the mean. Statistical significance was calculated by unpaired two-tailed test (* P<0.05, ** 
p<0.01, *** p<0.001) Representative experiment out of 3 repetitions. 
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Immuno-detection of S2 
 
S2 is a 6 KDa protein and the low molecular weight makes it difficult to detect 
in Western blotting. In addition, no commercial antibody is available. We 
therefore decided to increase gene expression by constructing an ORF 
optimized for human codon usage. To facilitate its detection, an HA-tag was 
added either at the N-terminus and at the C-terminus. The protein expressed 
by the codon-optimized gene was readily detected in immunoblotting 
experiments, however, the N-terminal addition of the HA tag appeared to 
impair expression and functionality of the protein. Codon-optimized S2 with a 
C-terminal tag, in contrast, showed the same level of rescue of Nef-defective 
HIV-1 infectivity as untagged S2 expressed from the native cDNA sequence. 
Having observed that the codon-optimized construct achieves the same 
effect as S2 expressed from the native sequence, but allows better S2 
immune-detection, this was used for all the experiments we performed 
thereafter (Figure 3.6). 
Constructs expressing S2 fused with both C-terminal GFP or RFP were also 
produced, but the proteins were non-functional and poorly detected and in 
our assay. (data not shown). 
 
Similarly to the activity of Nef, the ability of S2 to increase HIV-1 infectivity 
is envelope glycoprotein-dependent. 
 
Retroviruses can incorporate in their lipid envelope heterologous cell surface 
proteins. Accordingly, envelope pseudotyping is used to modify the tropism 
of retroviruses. The requirement of Nef for HIV-1 infectivity is known to 
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depend on the nature of the envelope glycoprotein used to pseudotype the 
virus85,113,114. HIV-1nef- infectivity was tested using different envelope 
pseudotypes in the absence and in the presence of S2 expression. When HIV-
1 is pseudotyped with the envelope glycoproteins derived from VSV-G and 
from the HIV-1 JR-FL isolate, the virus was found to be not Nef-responsive85. 
Similarly, expression of S2 in producer cells did not affect the infectivity of 
these virus particles, further suggesting that Nef and S2 target the same 
infectivity defect (Figure 3.7).  
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Figure 3.6 
Effect of S2 codon optimization and HA-tag addition on gene expression and function. 
a) Infectivity of Nef-defective HIV-1, obtained by JTAg electroporation ,  in the presence or in 
the absence of  S2 wt, HA-S2, S2-HA, codon optimized S2-HA (S2 COOPT). 
b) WB of corresponding cell lysates to evaluate the expression level of each S2 expression 
plasmid. 
 Nef-negative HIV-1 was obtained with a two-vector system composed by a NL4-3 derived plasmid 
deficient for env and nef and complemented with pbj5 expressing HIV-1HXB2env. 4:4:1 ratio 
between viral backbone, S2 wt/N-terminal HA tagged S2/C-terminal HA tagged S2/codon 
optimized C-terminal HA tagged S2/ or empty vector and env was used. Supernatant of producer 
cells was collected 48h post-transfection and used to infect TZM-GFP reporter cells, as described in 
materials and methods and analysed through automatized microscopy. Corresponding cell lysates 
were resolved by SDS-PAGE and analysed by WB. Infectivity values are average of 4 independent 
transfections (biological quadruplicates). Error bars represent standard deviation of the mean. 
Statistical significance was calculated by unpaired two-tailed test (* P<0.05, ** p<0.01, *** 
p<0.001). Representative experiment out of 3 repetitions. 
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Figure 3.7 
Envelope pseudotype dependence. 
a,b) Relative infectivity (% of the control Nef+ sample) of HIV-1 wt or Nef-negative 
pseudotyped with VSV-G or JR-FL  isolate envelope, in the presence or in the absence of  
EIAV S2-HA  provided in trans.  
       c,d)  Evaluation of expression level of S2 expression plasmid. 
HIV-1 wt or Nef-negative is obtained with a two-vector system composed by a NL4-3 derived 
plasmid deficient for env and for env and nef and complemented with pbj5 expressing VSV-G or 
HIV1JF-RLenv. 4:4:1 ratio between viral backbone, S2-HA or empty vector and env was used. 
Supernatant of producer cells was collected 48h post-transfection and used to infect TZM-GFP 
reporter cells, as described in materials and methods and analysed through automatized 
microscopy. Corresponding JTAg cell lysates are resolved by SDS-PAGE and analysed by WB. 
Infectivity values are average of 4 independent transfections (biological quadruplicates). Error 
bars represent standard deviation of the mean. Statistical significance was calculated by 
unpaired two-tailed test (* P<0.05, ** p<0.01, *** p<0.001). Representative experiment out of 3 
repetitions.  
 
 
 
Evaluation of expression level of S2 expression plasmid and actin used to normalize (c,d).  
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The involvement of endocytosis in S2 activity 
 
A conserved ExxxLL motif, potentially interacting with AP2, is present within 
the S2 aa sequence. To investigate its relevance for S2 activity on infectivity, 
the ExxxLL motif was mutated to ExxxAA and tested in our infectivity assay 
using Nef-defective HIV-1 (Figure 3.8a). As shown in Figure 3.9b, the mutant 
protein loses its ability to increase HIV-1 infectivity, despite the mutation not 
affecting protein expression in the producer cell lysates, demonstrating the 
functional importance of the LL motif.  
A potential SH3 binding PxxP motif is also present in S2 and adds another 
element of similarity with Nef. The PxxP motif is overlapping with the ExxxLL 
motif (ESQPLLP). We therefore investigated whether PxxP plays any role in S2 
activity by mutating both prolines into alanines (AxxA). The mutant protein 
resulted as active as the wt protein excluding a role of such motif in the 
infectivity effect (Figure 3.9). This is in line with the evidence that the similar 
PxxP sequence does not contribute to the effect of Nef on infectivity. The 
crucial role of the ExxxLL motif prompted further experiments to investigate 
the involvement of the endocytic machinery in the activity of S2. 
First, we investigated the intracellular localization of S2. Immunofluorescence 
microscopy was performed on JTAg cells transfected with the construct 
expressing S2-HA, stained with anti-HA antibody. Images revealed that the 
protein is localized at the plasma membrane and also present in a perinuclear 
compartment, reminiscent of the localization of Nef and glycoGag82. Indeed, 
when S2-HA was co-expressed together with Nef-GFP, the two proteins 
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colocalized, suggesting that, as demonstrated with Nef and glycoGag, S2 
associates with a late endocytic intracellular compartment (Figure 3.10). 
Then, we investigated whether clathrin-mediated endocytosis is required for 
S2 activity. We tested whether the effect of S2 is sensitive to inhibitors of the 
endocytosis machinery. The C-terminal fragment of AP-180 and the 
dynamin2 K44A transdominant negative mutant potently inhibit clathrin 
mediated vesicle biogenesis and were reported to inhibit the Nef effect80,115. 
In the presence of both inhibitors S2 failed to recover HIV-1nef- infectivity, 
indicating that a functional endocytic machinery is required for the ability of 
S2 to affect retrovirus infectivity. (Figure 3.8 c and d). 
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Figure 3.8 
Involvement of the EXXXLL motif on S2 activity. 
a) Schematic representation of amino acid sequence of S2-HA LL/AA mutant. 
b) Infectivity values and corresponding expression levels in cell lysates of Nef defective HIV-1  
alone and together with  S2-HA  wt or LL/AA S2 –HA  produced in JTAg cells 
c), d) Nef-negative HIV-1 obtained by transfection of JTAg cells in the presence or in the 
absence of S2-HA and two different endocytosis inhibitors separately tested: AP180 C-terminal 
and Dynamin K44A. 
Nef-negative HIV-1 was obtained with a two-vector system composed by a NL4-3 derived 
plasmid deficient for env and for env and nef and complemented with pbj5 expressing HIV-
1HXB2env. 4:4:1 ratio between viral backbone, S2-HA or empty vector and env was used. 1:1.5 
ratio between S2-HA and each endocytosis inhibitor tested separately was provided. 
Supernatant of JTAG producer cells was collected 48h post-transfection and used to infect TZM-
GFP reporter cells, as described in materials and methods and analysed through automatized 
microscopy. .Corresponding JTAg cell lysates are resolved by SDS-PAGE and analysed by WB. 
Infectivity values are average of 4 independent transfections (biological quadruplicates). Error 
bars represent standard deviation of the mean. Statistical significance was calculated by 
unpaired two-tailed test (* P<0.05, ** p<0.01, *** p<0.001). Representative experiment out of 
3 repetitions. 
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Figure 3.9 
Involvement of SH3 binding domain on S2 activity. 
a) Schematic representation of amino acid sequence of S2-HA ALLA mutant. 
b) Infectivity values of Nef-defective HIV-1 alone and together with S2-HA wt or ALLA S2–
HA mutant produced in JTAg cells. 
 Nef-negative HIV-1 was obtained with a two-vector system composed by a NL4-3 derived 
plasmid deficient for env and nef and complemented with pbj5 expressing HIV-1HXB2env. 4:4:1 
ratio between viral backbone, S2-HA/ALLA S2-HA or empty vector and env was used. 
Supernatant of producer cells was collected 48h post-transfection and used to infect TZM-
GFP reporter cells, as described in materials and methods and analysed through automatized 
microscopy. Infectivity values are average of 4 independent transfections (biological 
quadruplicates). Error bars represent standard deviation of the mean. Statistical significance 
was calculated by unpaired two-tailed test (* P<0.05, ** p<0.01, *** p<0.001). 
Representative experiment out of 3 repetitions.  
c)  
d)  
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Figure 3.10 
EIAV S2 intracellular localization. 
a) Confocal microscopy of JTAg cells transfected to drive the expression of S2-HA along with eGFP 
used as control. 
b) Confocal microscopy of JTAg cells transfected with S2-HA along with NefGFP to compare cellular 
localization. 
c) Confocal microscopy of JTAg cells transfected to drive the expression of Nef-GFP along with RFP 
used as control. 
 
a) 
c) 
Anti HA 
Anti HA 
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As already discussed, Nef is a myristoylated protein; on the other hand 
glycoGag is a type II transmembrane protein. In both cases, the ability to 
interact with the plasma membrane is a requirement for their effect on 
infectivity. We therefore investigated whether S2 presents some features 
which allow an interaction with the membrane. 
Using the transmembrane topology predictor TMpred, we evaluated whether 
S2 contains a transmembrane helix. The TMpred program functions using an 
algorithm based on the statistical analysis of TMbase, a database of naturally 
occurring transmembrane proteins. The prediction is made using a 
combination of several weight-matrices for scoring116. A putative TM domain 
was found by TMpred within the S2 hydrophobic region, between aa in 
position 33 and 55; we therefore tested whether this sequence is required for 
S2 activity by inserting several substitutions (Figure 3.11a) which disrupt the 
hydrophobic motif (Figure 3.11c). Accordingly, the mutated protein was no 
longer predicted by TMpred to contain a transmembrane helix. However, this 
modified S2 retained the ability to increase the infectivity of Nef-defective 
HIV-1, similarly to the wt protein, suggesting that the predicted 
transmembrane domain plays no functional role. 
Another mechanism which mediates association of proteins to the plasma 
membrane is via N-terminal myristoylation. Myristoylation is a co-
translational or post-translational modification derived from covalent 
addition of a myristic acid moiety at the N-terminal glycine residue of the 
protein. We therefore explored the possibility that S2, similarly to Nef, is 
myristoylated. 
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Interestingly, Yoon et al.112, suggested that S2 contains a putative 
myristoylation signal. While the aa sequence of myristoylation signals is not 
well defined, a glycine at the N-terminal is required117. Interestingly, a N-
terminal glycine in S2 is highly conserved. To investigate the role of such 
residue, a G to A mutation was inserted to generate an S2 variant that would 
not be myristoylated. Expressed in JTAg HIV-1 producer cells, the G2A 
mutant, expressed at a level similar to the wt protein, did not affect virus 
infectivity (Figure 3.12), indicating that the N-terminal glycine plays a crucial 
functional role, and supporting the hypothesis that this could be the 
substrate of myristic acid addition by the N-myristoyl transferase. 
To directly assess whether S2 is myristoylated in vivo, a CLICK chemistry-
based assay118 was used. HEK293T cells were transfected to drive the 
expression of S2-HA wt or the G2A mutant and cultured in the presence of 
azide-labelled myristic acid. Myristoylated proteins were then captured in cell 
lysates by alkyne-coupled beads. The presence of myristoylated S2 in the 
pull-down was verified by Western blot analysis using an anti-HA antibody. 
As shown in Figure 3.13, a signal was detected when S2 wt, but not the G2A 
mutant, was expressed. Confirming the significance of the assay, a similar 
result was obtained with Nef-HA used as a positive control. No signal was 
detected with Cyclophilin A-HA, a protein that is not myristoylated, or with 
Nef G2A mutant, both used as a negative controls.  
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Figure 3.11 
S2 protein topology investigation. 
a) Schematic representation of amino acid sequence of S2-HA TM mutant. 
b), c) bioinformatic prediction of putative transmembrane domains for S2 wt and S2 
mutant respectively. Red lines on figures indicate the threshold background. 
d) Infectivity values of Nef-defective HIV-1 alone and together with S2-HA wt or S2–HA 
transmembrane mutant. Nef-negative HIV-1 was obtained with a two-vector system 
composed by a NL4-3 derived plasmid deficient for env and nef and complemented 
with pbj5 expressing HIV-1HXB2env. 4:4:1 ratio between viral backbone, S2-HA wt/S2-
HA TM mutant  or empty vector and env was used. Supernatant of producer cells was 
collected 48h post-transfection and used to infect TZM-GFP reporter cells, as described 
in materials and methods and analysed through automatized microscopy. Infectivity 
values represent the average of 4 independent transfections (biological 
quadruplicates). Error bars represent standard deviation of the mean. Statistical 
significance was calculated by unpaired two-tailed test (* P<0.05, ** p<0.01, *** 
p<0.001). Representative experiment out of 3 repetitions. 
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Figure 3.12 
Importance of the N-terminal glycine for S2 activity. 
a) Schematic representation of amino acid sequence of S2-HA G2A mutant. 
b) Infectivity values and S2-HA and G2A S2-HA expression levels in corresponding cell 
lysates.  
Nef-negative HIV-1 was obtained with a two-vector system composed by a NL4-3 derived plasmid 
deficient for env and nef and complemented with pbj5 expressing HIV-1HXB2env. Electroporations 
are performed in JTAg used as producer cells. 4:4:1 ratio between viral backbone, S2-HA/ G2A S2-
HA or empty vector and env was used. Supernatant of producer cells was collected 48h post-
transfection and used to infect TZM-GFP reporter cells, as described in materials and methods 
and analysed through automatized microscopy. Corresponding JTAg cell lysates are resolved by 
SDS-PAGE and analysed by WB.  
Infectivity values are average of 4 independent transfections (biological quadruplicates). Error 
bars represent standard deviation of the mean. Statistical significance was calculated by unpaired 
two-tailed test (* P<0.05, ** p<0.01, *** p<0.001). Representative experiment out of 3 
repetitions. 
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Figure 3.13 
Detection of myristoylated S2. 
a) Click-IT chemistry methodology (for further information see materials and methods section). 
WB analysis of input (c) and enriched fraction (b) for detection of HA-tagged S2 wt, S2 G2A, Nef 
and Nef G2A mutant used as positive controls and hCyp used as negative control. 
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The S2 activity against SERINC5 
 
While investigating the role of S2 in infectivity, SERINC5 was identified by our 
laboratory as the retrovirus inhibitor counteracted by Nef and glycoGag85. 
Given that all the experiments in our hands demonstrated that S2 is 
functionally related to Nef and glycoGag, its ability to counteract SERINC5 
was therefore investigated next.  
To this end, two strategies were followed: 
 Testing whether the activity of S2 on HIV-1 infectivity in JTAg cells requires 
SERINC5 and SERINC3. This was achieved using a JTAgSERINC5-/- and the double 
knock out JTAgSERINC5-/- SERINC3-/- cell lines developed in our laboratory using a 
CRISPR-Cas9 vector. 
 Testing the ability of S2 to counteract exogenously expressed SERINC5 in a 
cell line which naturally lacks its expression. 
 
S2 counteracts SERINC5 and SERINC3 
 
Two JTAg-based cell lines were established in our lab using the PX458 CRISPR-
Cas9 vectors which express simultaneously the nuclease together with the 
specific sgRNA. The two cell lines where established sequentially by first 
targeting SERINC5 (JTAgSERINC5-/-) gene sequence and subsequently by 
targeting SERINC3 on the same cell line (JTAgSERINC5-/- SERINC3-/-)85. 
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As already reported, compared with the infectivity of HIV-1 produced in JTAg 
wt cells, Nef-defective HIV-1 from JTAgSERINC5-/- cells was 6-fold more 
infectious while the same virus from the double KO was 18-fold more 
infectious. This inversely correlated with the effect of S2 on infectivity of the 
Nef-defective virus which was 9-fold for virus produced in WT JTAg, 3-fold 
from virus derived from JTAgSERINC5-/-  and none for virus derived from the 
double knock out cells. This mirrors the effect of Nef on the same viruses and 
demonstrate that the effect of S2 requires SERINC5 and SERINC3 (Figure 
3.14). 
Furthermore, the effect of S2 was tested on ectopically expressed SERINC5. 
When Nef-defective HIV-1 was produced in HEK293T cells, which do not 
naturally express high levels of SERINC585, increasing ectopic expression of 
SERINC5 resulted in an increasing inhibition of the virus only in the absence 
of S2. In contrast, when S2 was present in the producer cells, the infectivity of 
the virus was preserved, irrespectively of the amount of SERINC5 being 
transfected, further demonstrating that S2 acts on HIV-1 infectivity by 
counteracting the host factor (Figure 3.15a). 
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Figure 3.14 
EIAV–S2 effect on HIV-1 produced in SERINC5 and SERINC3 DKO cells. 
Infectivity of Nef-negative HIV-1 obtained by electroporation of JTAg SERINC5 KO or SERINC5 and 
SERINC3 DKO, in the presence or in the absence of EIAV S2 or Nef used as positive control.  
Nef-negative HIV-1 was obtained with a two-vector system composed by a NL4-3 derived plasmid 
deficient for env and nef and complemented with pbj5 expressing HIV-1HXB2env.  4:4:1 ratio 
between viral backbone, S2 or empty vector and env was used. Supernatant of producer cells was 
collected 48h post-transfection and used to infect JTAG, JTAg SERINC5 KO or SERINC5 and 
SERINC3 DKO as described in materials and methods and analysed through FACS. Infectivity 
values are average of 4 independent transfections (biological quadruplicates). Error bars 
represent standard deviation of the mean. Statistical significance was calculated by unpaired two-
tailed test (* P<0.05, ** p<0.01, *** p<0.001). Representative experiment out of 3 repetitions. 
 
104 
 
105 
 
 
Figure 3.15 
EIAV–S2 effect in overexpressing condition of increasing amount of SERINC5 in Nef low 
responsive HEK293T cell line. 
a) Infectivity of HIV-1nef- virus produced in HEK293T cells in the presence of S2-HA and 0.125, 0.25 
and 0.5 µg of PBJ6 SERINC5-HA. 
Nef-negative HIV-1 was obtained with a two-vector system composed by a NL4-3 derived plasmid 
deficient for env and nef and complemented with pbj5 expressing HIV-1HXB2env.  4::4:1 ratio 
between viral backbone, S2 or empty vector and env was used. Supernatant of producer cells was 
collected 48h post-transfection and used to infect TZM-GFP reporter cells, as described in 
materials and methods and analysed through automatized microscopy. Infectivity values are 
average of 4 independent transfections (biological quadruplicates). Error bars represent standard 
deviation of the mean. Statistical significance was calculated by unpaired two-tailed test (* 
P<0.05, ** p<0.01, *** p<0.001). Representative experiment out of 3 repetitions. 
 Corresponding cell pellets were collected from both the soluble b) and the insoluble fraction c) 
resolved by SDS-PAGE and analysed by WB. d) S2-mediated degradation of 0.125, 0.250, 0.5 µg of 
CXCR4 receptor was also tested as negative control. 
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S2 promotes SERINC5 endocytosis 
 
As we have already demonstrated, clathrin-mediated endocytosis and a 
putative AP2 binding motif is crucial for the activity of S2 on infectivity. As it 
has been demonstrated that Nef and glycoGag cause SERINC5 accumulation 
from the cell membrane into the late endosomal compartment, we verified, 
using immunofluorescence microscopy, whether S2 could achieve the same 
effect. While JTAg transfected to express SERINC5-GFP together with a 
control vector expressing TagRFP, the host factor was almost exclusively 
localized on the cell surface. When cells were transfected to express S2-HA, 
on the other hand, the host factor appeared to accumulate, together with S2-
HA, into a perinuclear compartment. When vectors expressing S2-HA and 
SERINC5-GFP were co-transfected into JTAg cells together with a plasmid 
expressing RAB7-RFP, the host factor appeared to co-localize with the marker 
for late endosomes, indicating that, like Nef and glycoGag, S2 promotes 
SERINC5 endocytosis. (Figure 3.16) 
 
S2 prevents SERINC5 incorporation into virions 
 
We next assessed whether, in analogy with Nef and glycoGag, the effect of S2 
on SERINC5 intracellular localization reflects on the level of incorporation of 
the host factor into virus particles. Western blotting of pelleted Nef-defective 
HIV-1 produced by transfecting HEK293T cells also expressing SERINC5 
revealed that, while the host factor is readily detected when S2 is absent,  
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Figure 3.16 
EIAV S2 mediates SERINC5 re-localization into a late endosomal compartment. 
 Confocal microscopy of JTAg cells transfected to drive the expression of S2-HA a), SERINC5-GFP 
b) or S2-HA along with SERINC5-GFP c). GFP and RFP are used as control respectively for panel a) 
and b) 
Confocal microscopy of JTAg cells transfected with SERINC5-GFP together with Rab7-RFP, in the 
presence d) or in the absence of S2 e). (S2 is not shown in panel d and e) 
Representative experiment out of 3 repetitions. 
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when the EIAV factor is expressed, SERINC5 is mostly excluded from virus 
particles. Like Nef and glycoGag, therefore, S2 prevents virus incorporation of 
SERINC5 (Figure 3.17). 
Western blotting of producer cell lysates revealed that the level of steady 
state expression level of SERINC5 was markedly decreased when S2 was co-
expressed. This evidence, which could indicate that S2 promotes degradation 
of SERINC5, was further investigated.  
 
S2 affects the steady-state expression level of SERINC5 
 
HEK293T cells were cotransfected with pcDNA3.1 S2-HA along with increasing 
amounts of a pcDNA3.1 SERNIC5-HA. To take into account possible effects 
deriving from promoter competition, the total amount of plasmid transfected 
was equalized among samples by adding empty pcDNA3.1 vector. Western 
blot analyses from the soluble fraction of lysates produced by lysing cells with 
a DDM-based buffer revealed that while SERINC5 was readily detected in the 
absence of S2 expression, the presence of the EIAV accessory protein 
resulted in a drastic decrease of SERINC5 expression, irrespectively of the 
amount of SERINC5-HA plasmid transfected. 
The same result was observed when the insoluble fraction of the cell lysates 
was analysed. This excludes the possibility that failed SERINC5 detection in 
the lysate could be explained by the formation of SERINC5 insoluble 
aggregates caused by S2, and lost when the cell lysate is clarified by 
centrifugation. 
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To further investigate whether this effect is SERINC5-specific, we investigated 
whether S2 affects steady state expression level of another multispanning 
transmembrane protein (CXCR4-Flag) expressed from the same vector 
(pcDNA3.1). Results show unequivocally that S2 does not affect CXCR4-FLAG 
expression, indicating that its effect on SERINC5 is specific and suggesting 
that the EIAV protein could promote a fast degradation of the host restriction 
factor (Figure 3.15). 
 
S2 is incorporated into retrovirus particles 
 
Figure 3.17 indicates that S2 is associated into retroviral particles. This is 
reminiscent of the evidence that Nef, which is myristoylated, is also found 
incorporated into HIV-1 virions. Nef is thought to be taken up passively into 
viral particles, as a consequence of its propensity to localize with the cell 
membrane. We further investigated whether the presence of S2 depends on 
the myristoylation of the EIAV protein or on its putative ability to interact 
with AP2. Western blotting of HIV-1 producer HEK293T cells expressing S2-HA 
or the G2A and ExxxAA mutants pelleted through a sucrose cushion revealed 
that in all three cases the protein is equally and abundantly associated with 
viral particles, indicating that virus incorporation of S2 is independent of the 
protein myristoylation or its possible association with AP2. Together with the 
evidence already discussed, that both mutants are defective for the ability to 
increase virus infectivity, this result also suggests that the activity of S2 on 
infectivity does not depend on its ability to associate with virion particles. 
(Figure 3.18) 
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Figure 3.17 
EIAV–S2 decreases the amount of SERINC5 both incorporated into virion and in 
cell lysates.  
 Viral particles were isolated by ultracentrifugation of supernatant of HEK293T producer 
cells, transfected with HIV-1nef- virus alone or along with SERINC5 and SERINC5 plus S2-HA. 
The obtained virions and corresponding lysates were resolved by SDS-PAGE and analysed by 
WB. Representative experiment out of 3 repetitions. 
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Figure 3.18 
S2 incorporation into viral particles. 
Viral particles were isolated by ultracentrifugation of the supernatant of JTAg producer cells, 
transfected with HIV-1nef- virus alone or along with S2-HA, G2A, S2-HA LL/AA S2-HA. The obtained 
virions and corresponding lysates were resolved by SDS-PAGE and analysed by WB. 
Representative experiment out of 3 repetitions. 
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The effects of SERINC5 and S2 on EIAV infectivity 
 
Most of the experiments to investigate the activity of S2 on retrovirus 
infectivity were conducted using HIV-1 as a model system. This mainly 
because reagents and assays to study HIV-1 infection are readily available 
and robust. The activity of EIAV LTR is low in most cell lines, making it difficult 
to use the entire provirus to study EIAV infection. Systems to produce 
recombinant EIAV in human cells exist. However, beside the fact that EIAV 
capsid is targeted by human TRIM5, these vectors are commonly and 
exclusively used as VSV-G pseudotypes, which are not suitable for our 
experiments. For our purposes, we obtained a plasmid expressing EIAV Env 
derived from the pSPEIAV19 isolate, which allowed us to pseudotype EIAV 
particles derived from a three-part vector system, packaging a GFP reporter 
gene. A construct encoding the EIAV packaging functions was mutated in 
order to disrupt the S2 ORF to produce S2-defetive vectors.  
A retroviral vector encoding the EIAV receptor, ELR1, was also obtained, 
which we used to generate EIAV permissive cell lines stably expressing the 
receptor. Two stable lines expressing ELR1 were generated, based on TZM-bl 
and JTAg. EIAV vectors were produced in the presence and absence of 
SERINC5 and S2 by transfecting HEK293T cells. Infectivity of virus particles 
was measured by flow cytometry on both permissive cell lines. In contrast to 
results from the previous experiments with HIV-1 vectors, in conditions which 
results in a 10 to 50-fold effect on infectivity, the effect of SERINC5 on EIAV 
vector infectivity was negligible. While the infectivity of EIAV vectors was not 
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affected by SERINC5 when TZM-bl or Jurkat-ELR1 cells were used as target 
cells. Accordingly, S2 had little effect on the infectivity of the virus. This result 
suggests that EIAV vectors are resistant to the inhibition by SERINC5 
independently on the presence of S2 (Figure 3.19). Previous results in the lab 
suggest that heterologous envelope glycoproteins promoting retrovirus 
fusion into a endocytic vesicle render the virus particle resistant to SERINC5. 
Interestingly, EIAV Env was reported to mediate infection via a pH-dependent 
entry pathway9,10. We therefore investigated whether EIAV Env is capable of 
making retrovirus particles resistant to SERINC585. To this end, HIV-1 was 
pseudotyped with EIAV Env and produced in the presence or absence of 
SERINC5. The infectivity of the virus was marginally affected (3-fold) in the 
presence of SERINC5, while in the same conditions, HIV-1 bearing native Env 
was inhibited 16-fold, indicating that EIAV Env confers at least partial 
resistance to SERINC5. The presence of S2 was sufficient to rescue the 
infectivity of the virus regardless of Env used for pseudotyping (Figure 3.20). 
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a) 
b) 
 
Figure 3.19 
Importance of SERINC5 and S2 for EIAV infectivity using different target cell lines. 
Infectivity of S2-negative EIAV , produced in HEK293T cells in the presence or in the absence of 
SERINC5 and S2 provided in trans. 
S2-negative EIAV was obtained with a three-vector system composed by pEIAV53D, pw sin6.1 and 
pLG338/30 vectors with a 2:2:1 ratio. S2 and SERINC5 are also provided with 1.5:1 ratio. 
Supernatant of producer cells was collected 48h post-transfection and used to infect TZM-bl ELR1 
(a) or JTAg ELR1 (b) as described in materials and methods and analysed through FACS. Infectivity 
values are average of 4 independent transfections (biological quadruplicates). Error bars 
represent standard deviation of the mean. Statistical significance was calculated by unpaired two-
tailed test (* P<0.05, ** p<0.01, *** p<0.001). Representative experiment out of 3 repetitions.  
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b) 
a) 
Figure 3.20 
EIAV Env acts synergistically together with S2. 
Infectivity of Nef-negative HIV-1 produced in HEK293T cells in the presence or in the absence of 
SERINC5 or SERINC5 plus S2 HA supplemented in trans and pseudotyped with HIV-1 a) or EIAV 
envelope b).  
Nef-negative HIV-1 was obtained with a two-vector system composed by a NL4-3 derived 
plasmid deficient for env and nef and complemented with pbj5 expressing HIV-1HXB2 env or   
pLG338/30 EIAV env 4:4:1 ratio between viral backbone, S2 or empty vector and env was used. 
Supernatant of producer cells was collected 48h post-transfection and used to infect TZM-GFP 
reporter cells, as described in materials and methods and analysed through automatized 
microscopy. Infectivity values are average of 4 independent transfections (biological 
quadruplicates). Error bars represent standard deviation of the mean. Statistical significance was 
calculated by unpaired two-tailed test (* P<0.05, ** p<0.01, *** p<0.001). Representative 
experiment out of 3 repetitions. 
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Discussion 
 
Our research has identified S2 as a Nef-like infectivity factor. While my 
research was developing, SERINC5 was identified as the host restriction factor 
targeted by Nef and glycoGag. I here showed that S2 is also capable of 
counteracting the anti-viral activity of SERINC5. Altogether, this highlights the 
pressure posed by the host factor on diverse retroviruses, which evolved 
counteracting measures independently. In fact the three retrovirus factors 
are encoded from different locations of the retrovirus genome and they 
share no sequence homology. The evidence that viruses adapted to humans, 
rodents and ungulates are all capable of acting similarly on human SERINC5 
denotes a broad spectrum of their antagonizing activity. This is quite unusual 
if compared to other antagonizing factors. For example, EIAV Env was found 
to be the counteracting factor of BST2. But while it strongly antagonizes the 
activity of the equine allele, EIAV Env has no ability to counteract human 
BST2. Similarly, while glycoGag from MLV was recently uncovered to 
counteract also the antiviral factor APOBEC329, its antagonizing activity is 
restricted to the murine allele, since glycoGag has no effect against human 
APOBEC3G. The absence of species-specificity in the case of SERINC5 could be 
the consequence of its high degree of conservation among different species 
compared, for example, with BST2. Assuming that the counteracting factor 
interact directly with SERINC5, one possibility could be that all antagonizing 
factors recognize a similar moiety of the host factors, which remains the 
same because it is required for an unidentified conserved cellular activity. 
Unveiling the molecular features of the interaction with SERINC5 will be 
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required to comprehend the low species-specificity barrier behind the 
counteracting activity of S2, glycoGag and Nef. 
similarly to Nef and glycoGag, S2 was found to induce the relocalization and 
prevent virion incorporation of SERINC5. However in respect to Nef and 
glycoGag, S2 also greatly affects the steady state level of SERINC5. This effect 
specifically targets SERINC5, since another multipass transmembrane protein 
(CXCR4) was not affected by S2. This may indicate the ability of S2 to promote 
SERINC5 degradation, but further studies will be required to fully prove this 
hypothesis. Generally, transmembrane proteins are degraded by being 
routed into the lysosomal compartment, in particular by being degraded into 
multivesicular bodies. This implies that, like a protein degraded by the 
proteasome, the transmembrane protein is ubiquitinated. Future studies 
should therefore investigate whether SERINC5 is ubiquitinated in the 
presence of S2 and whether inhibitors of the lysosomal maturation affect the 
ability of S2 to decrease SERINC5 expression levels. 
S2 was found incorporated into retrovirus particles, an evidence which was 
never reported before. The meaning and the mechanism of S2 virion 
incorporation remain unknown and is reminiscent of the ability of Nef to 
associate not only with HIV-1 but also with heterologous virus particles119. 
Like in the case of Nef, the ability of S2 to associate with virions seems 
unlikely to play a role on infectivity, since mutations impairing putative AP2 
binding and the N-terminal myristoylation, both of which ablate the function 
on infectivity, do not affect S2 virion incorporation. 
While most experiments to characterize the activity of S2 against SERINC5 
were performed in the context of HIV-1, my attempts to study the role of S2 
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in the context of EIAV revealed that the equine lentivirus vector particles we 
used are substantially refractory to inhibition by SERINC5. A possibility we did 
not verify is that EIAV could be sensitive to equine SERINC5 but resistant to 
the human allele. However, we found that the EIAV Env glycoprotein we used 
has the inherent ability to render also HIV-1 more resistant to SERINC5. This 
is similar to what has been observed with some Env glycoproteins of HIV-1 
and MLV. HIV-1 Env from some primary isolates, such as for example JR-FL, 
were shown to make the virus unresponsive to Nef by making it resistant to 
SERINC5. Similarly, Env from MoMLV was observed to confer 
unresponsiveness to glycoGag by making MLV resistant to SERINC5. 
Interestingly, EIAV Env was shown to promote virus particle fusion via a pH-
dependent pathway, which makes it similar, in this regard, to the Env 
glycoprotein of ALV, VSV, Ebola and influenza HA. As all of these 
glycoproteins share the ability to confer resistance to SERINC5, it is possible 
that fusion via an endosomal route could automatically provide a SERINC5-
resistant entry pathway. As shown with VSV-G and Ebola-GP, in fact, these 
glycoproteins do not act by preventing SERINC5 incorporation into virions but 
rather make virus particles non-sensitive to the effect of SERINC5 in the 
particles85. It will be interesting to verify whether this is the mechanism by 
which also EIAV Env works. In addition, having tested the effect of only one 
EIAV env allele, it would be interesting to investigate whether this is a general 
property and verify if, like in the case of HIV-1, Env glycoproteins from 
different EIAV isolates differ for their ability to confer SERINC5 resistance. In 
any case, a question arises: why did EIAV (like HIV and MoMLV) evolve a 
SERINC5-counteracting gene if Env alone can confer SERINC5 resistance? 
Assuming this is not the consequence of the limitation of our experimental 
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setting (it is possible that, for example, a defective infectivity would be visible 
using different cells as targets, such as, in the case of EIAV, primary equine 
monocytes which are the natural target in vivo) one simple explanation 
would be the need of viruses to develop redundant mechanism to ensure 
efficient counteraction. An insightful precedent could, for example, be the 
ability of HIV-1 to target CD4 with both Nef and Vpu to ensure efficient 
downregulation of the receptor. One additional possibility is that the anti-
viral activity of SERINC5 is not limited to targeting the virus particle 
infectivity, but extends to another, yet unidentified, aspect of virus 
replication. By analogy with BST2, one suggestive hypothesis is that SERINC5 
could also play a role in the anti-retroviral innate immunity by providing one 
additional mechanism to sense the retroviral pathogen. 
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 Chapter 4: Assessing the role of the SERINC 
gene family in influenza virus infection 
 
Introduction  
 
Influenza A is an enveloped virus belonging to the Orthomyxoviridae family. 
Its genome is composed by eight segments of ssRNA able to drive the 
synthesis of new influenza virus particles. 
After entry, negative sense RNA is reverted to positive by an RNA-dependent  
RNA-polymerase120, which is then used as a template for viral proteins 
production (Figure 4.1).  
The virus originally infects aquatic birds but acquires the ability to infect 
other species thanks to its high genetic flexibility. A central role in the 
adaptation process is played by intermediate hosts121. 
The HA and NA genes encode for the viral proteins inserted into the influenza 
A envelope. They are highly variables in sequence and allow the classification 
of the virus according to their subtype. It has been estimated that there have 
been at least 14 pandemics in the last 500 years, of which the last five were 
well documented122. The H3N2 Hong Kong pandemic emerged during 1968 as 
product of triple recombination between the previous seasonal H2N2 and the 
avian PB1 and HA subtype 3 genes. In 2009, after a triple recombination 
between classical swine H1N1, avian H1N1 and seasonal H3N2 a H1N1 
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pandemic virus evolved which caused more than 200000 deaths123 (Figure 
4.2). 
The A/Victoria/3/75 and the A/England/195/2009 I used for my studies 
derived from epidemic H3N2 and pandemic H1N1 respectively.  
Influenza A virus is restricted by IFN-inducible transmembrane proteins 
(IFTM); IFITM1, 2, 3, act at the level of virus entry, inhibiting fusion between 
virus end cell membranes. This family inhibits replication of multiple 
pathogenic viruses including DENV, SARS, CoV, EBOV, MARV and HIV-1124. 
IFTMs represent an example of host factors having activity across several viral 
families. 
While the inhibitory effect of SERINC5 has been established on retroviruses, 
nothing is yet known about its effect on viruses belonging to other families. 
Given that SERINC gene products are transmembrane proteins and are likely 
to gain access to the virus particle via association with the virus lipid 
envelope, it is conceivable to hypothesize that SERINC proteins could 
potentially be found associated with enveloped viruses and therefore act as 
potential inhibitors of viruses not belonging to the Retroviridae family. If this 
is the case, it is also conceivable that, as observed with different retroviruses, 
other viruses could have developed the ability to counteract these inhibitors. 
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Figure 4.2 
Evolution of Human Influenza A viruses. 
Wendel, I., Matrosovich, M.,  Klenk, H. D., Cell Host Microbe. ; 17(3):416.e1, (2015).  
Figure 4.1 
Influenza A genome organization. 
http://www.virology.ws/2009/05/01/influenza-virus-rna-genome/ 
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Results  
 
Expression of SERINC5 impairs production of 
infectious influenza A 
 
To investigate whether SERINC5 affects the infectivity of influenza virus, 
HEK293T cells already transfected to express increasing amount of the host 
retrovirus restriction factor, were infected with influenza A. Progeny virus 
particles were used to infect MDCK target cells and infection level measured 
by a plaque assay. 
The plaque assay on target cells infected by serially diluted viral inocula is 
based on the assumption that each plaque formed is representative of one 
infective virus particle (Figure 4.3).  
Ectopic expression of SERINC5 in producer cells resulted in a strong inhibition 
of both England195 and Victoria75 influenza A viruses. This experiment 
suggests that SERINC5 is able to modulate infectivity of the virus in a dose-
dependent manner, with a 50-fold reduction at the highest amount of the 
SERINC5 expression plasmid we used (Figure 4.3). 
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Figure 4.3  
Victoria and England strains of infuenza A are inhibited by SERINC5. 
Overexpession of increasing amounts of SERINC5 in HEK293T producer cells leads to a dose – 
dependent reduction in infectivity of both England and Victoria strains of human influenza A virus.  
HEK 293T cells were transfected with 50/100/200 ng of SERINC5 PBJ6 and infected the day after 
respectively with  3.1x107 MOI and 3.9x107 MOI of Eng195 or Vic75 strain of influenza A. Viruses are 
collected 24h post infection and used to perform a plaque assay. PFU/ml values are average of 4 
independent transfections (biological quadruplicates). Error bars represent standard deviation of 
the mean. Statistical significance was calculated by unpaired two-tailed test (* P<0.05, ** p<0.01, 
*** p<0.001). Representative experiment out of 3 repetitions.  
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The effect of SERINC5 does not target the intrinsic 
infectivity of influenza virus 
 
Having observed an inhibitory effect of SERINC5 on the production of 
infectious influenza A, we next investigated whether the host factor, like in 
the case of HIV-1, impaired intrinsic infectivity. As described above, virus was 
produced by infecting HEK293T cells expressing SERINC5 or an empty vector 
control. Virus titre measured by plaque assay was inhibited 50-fold by the 
expression of SERINC5. The amount of virus released was evaluated by 
quantifying the virus RNA encoding for the matrix gene in the supernatant of 
producer cells, using qRT-PCR. Results show that the supernatant from 
SERINC5 expressing cells contains 100-fold less influenza virus RNA than the 
control sample. Altogether these data suggest that SERINC5 does not affect 
the intrinsic infectivity of influenza A virus (Figure 4.4). It is therefore possible 
that the host factor expressed in HEK293T cells acts by inhibiting influenza A 
production/release. However, because in our experimental setting, influenza 
A was produced by infecting HEK293T cells already over-expressing SERINC5, 
the possibility remains that the host factor acted upstream by preventing 
infection of these cells, therefore functioning as influenza inhibitor in target 
cells. Unfortunately, I could not investigate further to discriminate between 
these two possibilities as I had limited time available in Wendy Barclay’s 
Influenza Laboratory. 
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Figure 4.4 
The effect of SERINC5 does not target the intrinsic infectivity of influenza A. 
a) Plaque assay and corresponding quantification b) of influenza A virus produced in the 
presence and in the absence of SERINC5. 
HEK 293T cells were transfected with 100 ng of SERINC5 PBJ6 and infected the day after with  
3.1x107 MOI of Eng195 strain of influenza A. Viruses are collected 24h post infection and used 
to perform a plaque assay. In parallel, same viruses were retro-transcribed and used to 
perform a Real Time PCR to quantify viral particles present in the supernatant of the infected 
cells in the presence or in the absence of SERINC5. PFU/ml values are average of 4 
independent transfections (biological quadruplicates). Error bars represent standard 
deviation of the mean. Statistical significance was calculated by unpaired two-tailed test (* 
P<0.05, ** p<0.01, *** p<0.001). Representative experiment out of 3 repetitions.  
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. 
SERINC3 and SERINC2 are also able to inhibit human 
influenza A 
 
As already reported, not only SERINC5, but also SERINC3 acts as retrovirus 
inhibitor. We therefore investigated whether any other SERINC gene is able 
to inhibit the infection of human influenza A virus. The effects of SERINC5, 
SERINC3 and SERINC2 on the England 195 influenza A strain was therefore 
tested. 
Results show that all SERINC genes tested inhibit influenza A with an 
efficiency similar to IFTM3, a well-established inhibitor of orthomyxoviruses. 
Interestingly, SERINC2, which in our laboratory was shown to have no activity 
against HIV-1 (unpublished), has instead a marked effect on influenza A 
(Figure 4.5). 
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Figure 4.5 
Not only SERINC5, but also SERINC3 and SERINC2 inhibit influenza A. 
Overexpression of SERINC5, SERINC3 or SERINC2 in HEK293T producer cells inhibit infectivity of 
England strain of influenza A virus. 
IFTIM3, established restriction factor of influenza A virus, was used as a positive control. HEK 
293T cells were transfected with 100 ng of SERINC5/3/2 PBJ6 and infected the day after with 
3.9x107 MOI of Vic75 strain of influenza A. Viruses are collected 24h post infection and used to 
perform a plaque assay. PFU/ml values are average of 4 independent transfections (biological 
quadruplicates). Error bars represent standard deviation of the mean. Statistical significance 
was calculated by unpaired two-tailed test (* P<0.05, ** p<0.01, *** p<0.001). Representative 
experiment out of 3 repetitions 
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Discussion 
 
This chapter describes a preliminary work performed during my one month 
internship in Professor Barclay’s lab at Imperial College, London. 
Being the SERINC proteins transmembrane, it is plausible to hypothesize that 
not only retroviruses but other enveloped viruses would also incorporate 
them during the virion budding process. Indeed, it would be interesting to 
verify whether SERINC5 or SERINC3 are found associated with other 
enveloped viruses. In any case, my preliminary experiments indicate that 
overexpression of SERINC2, 3 and 5 in virus producing cells all impair 
influenza A, at a step which remains to be identified. However, unlike the 
effect of SERINC5 and SERINC3 on HIV-1, my experiments show that the host 
factors do not impair intrinsic virus infectivity, pointing to an effect at the 
level of virus production, which could include virus release or virus gene 
expression. Since the virus for these experiments was produced by infecting 
cells already overexpressing the SERINC genes, the possibility also exists that 
the host factors interfere with influenza A entry. While we are at this 
moment unable to discriminate between these possibilities, the result 
obtained so far is encouraging because it describes a large dose-dependent 
effect, it was reproduced in 3 independent experiments, it was similarly 
obtained with three SERINC genes (SERINC5, SERINC3 and SERINC2), and 
observed using  two different strains of human influenza A: England195 and 
Victoria75. 
While SERINC5 is predominantly expressed in blood cells and in the CNS, 
other SERINCs, such as SERINC3, are express ubiquitously, including in airway 
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epithelial cells, the natural target of human influenza A virus, indicating that 
our preliminary observation could be relevant to the in vivo infection. 
If SERINC proteins are able to inhibit influenza, then it is possible that the 
virus has evolved a mechanism to minimize or escape from the control of the 
host restriction. The evolution of our study will therefore include 
understanding whether the influenza A virus has developed a factor capable 
of counteracting the antiviral activity of SERINC genes. 
By analogy with Nef, glycoGag and S2, the protein encoded by this gene 
would require the ability to interact with membranes and to recruit the 
endocytic machinery. After investigating the amino acid sequence of all 
proteins encoded by human influenza A virus, a YxxL and E/DxxxLL motifs 
were found in M1 and M2, both of which have the ability to associate (M1) or 
interact (M2 is a transmembrane protein) with the membrane.  (Figure 4.6). 
Future experiments will address these possibilities. 
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Figure 4.6 
M1 protein localization and amino acid sequence.  
Adapted from 
 
http://www.vetmed.fuberlin.de/einrichtungen/institute/we05/arbeitsgruppen/zellbiol
ogie/inhalt/index.html 
(Accession number: DQ415350.1) 
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Chapter 5: General conclusions 
 
During the long co-evolution between host and parasite, cells developed 
restriction factors to avoid virus replication and dissemination. These 
proteins are a first line of defence against viral pathogens and include a 
plethora of factors with a no-univocal structure that may act at every level of 
the viral life cycle. Restriction factors were developed to act against 
conserved viral components, (viral genomes; membranes) and in some cases 
evolved to be effective against different viral families. The SERINC proteins 
are the latest addition to the growing list of restriction factors. After our lab 
demonstrated that primate lentiviruses and gammaretroviruses have evolved 
SERINC antagonizing factors, with my research I have demonstrated that a 
counteracting factor was also evolved by EIAV, identifying a third event of 
convergent evolution leading to anti-SERINC activity.  
Convergent evolution is “the process whereby organisms not closely related 
(not monophyletic), independently evolve similar traits as a result of having 
to adapt to similar environments or ecological niches” 125(Figure 5.1). SERINC 
proteins provide an important element in the environment, to which at least 
three different virus groups had to adapt. This underlines a fundamental 
importance of the ability to counteract SERINC5. Accordingly, Nef, glycoGag 
and S2 are all similarly crucial pathogenic determinants126. 
There is yet no cure and eradication strategies for diseases caused by 
retroviruses, a problem particularly evident in the case of the HIV pandemic. 
By highlighting the importance of the SERINC5-Nef-like factors, my work 
133 
 
indicates a potential focus for novel antiviral strategies, needed to 
complement the current therapies. 
Nef and other Nef-like infectivity factors have no enzymatic activity, making it 
difficult to develop effective drugs targeting their activities. Once future 
studies will have elucidated the molecular interaction between the Nef-like 
factors and SERINC proteins, molecules interfering with such interaction 
could be designed. While the development of clinically active drugs to target 
protein-protein interaction remains problematic, promising progresses were 
made in recent years with the development of molecules able to target 
Nef127,128 and Vif129 activities and providing important proofs of principle.  
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Figure 5.1 
Convergent evolution schematic representation. 
http://www.sparknotes.com/biology/evolution/patternsofevolution/section1.rhtml 
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Chapter 6: Materials and methods 
Plasmids 
 
For all experiments performed with HIV-1, NL4-3 derived plasmids deficient  
for env and/or nef were used as described in Pizzato et al.80 Env defective 
viruses were complemented with pbj5 expressing HIV-1HXB2env. HA-GlycoGag 
NA, and the RXR/AXA mutant were obtained by site-directed mutagenesis. 
FeLV-A gg and KoRV gg  were isolated from the corresponding FeLV-A and 
KoRV522 molecular clones130 kindly provided by Prof Takayuky Miyhazawa, 
(Institute for Virus Research, Kyoto University), PERV glycoGag was amplified 
from PERV-A molecular clone kindly provided by Dr Yasuhiro Takeuchi (UCL, 
London). GALV gg was obtained by retrotranscribing with specific primers 
RNA extract from the A3.01/F7 cells line, recognized to be permanently 
infected with GALV. The 5’ 288nt of all glycolGag alleles were cloned and 
used to replace the homologous region within MoMLV glycoGag (HA-gg196) 
up to a stretch of highly conserved amino acids, which include a AflII 
restriction site in the MoMLV genetic sequence. An HA N-terminal tag was 
also added to facilitate the detection (Figure 6.1). Synthetic fragments 
(GeneArt, Life Technologies) encoding for codon optimized BIV TMX 
(AAA64394.1) and WDSV ORF2 (NP_045940) fused to a HA C-term tag, were 
cloned and inserted in a pbj5 expression vector using the in-fusion strategy 
(Clontech) according to the manufacturer guidelines. pcDNA based Orf-A 
from the Petaluma strain fused to an HA tag was a gift from Prof. Mauro 
Pistello (University of Pisa, Italy).  EIAV S2 with and without C-terminal HA tag 
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was amplified from p19/wenv16 EIAV molecular clone (af028231.1) and 
inserted into the pbj5 expression vector between EcoRI and NotI restriction 
sites. Codon-optimized version of S2-HA was obtained through a seven-step 
PCR, which allowed the sequential substitution of the required triplets 
according to the human codon usage. Codon optimized S2-HA was used as a 
template to generate Wyoming S2-HA (m87581), by inserting point 
mutations at positions 3 (V->L) and 18 (E->G); again, was chosen as 
expression vector. The same strategy already mentioned for S2 was used to 
codon optimize Orf-A HA.  
MLV and glycoGag-negative MLV have been modified to express GFP instead 
of env and supplemented by MLV-NZB-9-1 envelope glycoproteins expressed 
with a pCDNA-based vector. A plasmid encoding the vescicular stomatitis 
virus G protein (pMD.G) was used as already described, as well as env from 
the HIV-1 JRFL isolate131. All S2 mutants (L27L28->AA, G2->A myristoylation 
mutant, P26P29->AA) were generated by PCR-based mutagenesis. The 
hydrophobic region mutant was obtained by mutating LIVII at positions 45 to 
49, into SSVSS. pBJ6 vector was used to drive low expression levels of 
SERINC5-HA as already described85. SERINC5-GFP was previously generated in 
our lab and used accordingly85. pEIAV53D and pw sin6.1 cgfpw 
(M87581,Addgene) were used to  generate EIAV vectors. The first is a plasmid 
encoding EIAV packaging functions from Wyoming strain genome, with a 
deletion in the LTR sequence, a deletion of the viral packaging signal, a 
deletion of the first exon of tat and an extensive deletion of the env gene. 
The second is a lentiviral vector driving the expression of GFP. 
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A pEIAV43D (packaging construct) mutated in S2 sequence was obtained by 
enzymatic digestion with BamHI followed by a fill-in and ligation to insert 
frameshift disrupting the S2 ORF. EIAV codon optimized envelope pglSUTM 
was kindly provided by Susan Carpenter, (Washington State University). e-
GFP, RFP, Rab7-RFP, AP180 C-terminal transdominant mutant, K44A 
dynamin2 mutant, Nef-HA G2A mutant, hCypA, Nef-HA were used following  
previous reports.80,82,85,115  All constructs were confirmed by sequencing. 
 
Growing condition of EIAV envelope expression 
plasmid 
 
Codon-optimized EIAV envelope inserted in pLG338/30 vector was amplified 
in E. coli Stbl2 strain at 30°C for 20 hours. The combined effect of codon 
optimization and amplification in a low copy number plasmid resulted in an 
increase in the stability of the EIAV env, as reported132. 
 
Generation of stable cell lines 
 
To generate ELR1 stable cell lines, retroviral vectors encoding the equine 
receptor were obtained by co-transfection of MLV based pcg-gag-pol, pFB 
ELR1 transfer vector, and VSV-G env in HEK293T by calcium phosphate 
transfection. Vectors were collected 48h post-transfection and used to 
transduce TZM-bl cells spinoculated for 2h at 3000rpm.  TZM-bl single cell 
cloning strategy was applied to obtain a cell line expressing ELR1 
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homogenously. A similar protocol was adopted for generation of JTAg stable 
expressing ELR1. JTAg SERINC5-KO and SERINC5/SERINC3 double KO were 
previously generated in our lab with a CRISPR-Cas9 technology85. 
 
Cell lines and culture conditions 
 
JTAg, CEMX174, JTAg SERINC5 KO, SERINC5/3 DKO and JTAg ELR1 were 
cultured in suspension. Life Techonologies RPMI 1640 + 10% of heat 
inactivated fetal bovine serum FBS supplemented with 2mM L-Glutamine was 
used as a growth medium. The adherent TZM-GFP and TZM-bl ELR1, TE671, 
HEK293T and COS-7 cell lines were grown in Life Techonologies DMEM 
supplemented with 10% FBS and 2mM L-Glutamine.  
Madin-Darby canine kidney (MDCK) cells (ATCC) were maintained in cell 
culture media (Dulbecco’s modified Eagle’s medium (DMEM; Life 
Techonologies) supplemented with 10% fetal calf serum (FCS) (Biosera) and 
with 1% Penicillin-Streptomycin (Life Techonologies). 
Cultures were maintained in humidified incubators at 37°C and 5% C02. All 
cells lines resulted negative when routinely screened for possible 
mycoplasma contamination. 
Retroviruses production and infectivity assays 
 
All retroviruses infectivity data were obtained producing single round 
replication viruses by transfection. CEMX174 and JTAg were electroporated in 
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0.2cm gap electroporation cuvettes (Biorad) using 140V and 1000uF with 
exponential decay. Fresh medium was added to the cells the day before 
transfection; 106 cells/sample and 20µg of total DNA were used. HEK293T and 
TE671 were transfected by the calcium phosphate co-precipitation method. 
Cells were seeded the day before transfection in 10 cm plates to be 50% 
confluent at transfection. Culture supernatants containing HIV-1 or Nef-
deficient HIV-1, were obtained with a two-vector system composed by a NL4-
3 derived plasmid deficient for env or for env and nef and complemented 
with pbj5 expressing HIV-1HXB2env. A 4:4:1 ratio between viral backbone, the 
tested infectivity factor and envelope expressor respectively was used. 48h 
after transfection, viruses are collected, clarified by centrifugation at 300g for 
5 min and passed through filters with 0.45-µm pores. Viruses produced from 
quadruplicate transfections were then quantified using the SG-PERT reverse 
transcription assay (described in the following section), diluted serially (3 
fold) and used to infect target cells. TZM-GFP were seed 5000 cells/well in 96 
well plates the day before transfection. Infection of reporter cells was scored 
using the nuclei with Hoechst 33342 for each virus dilution. Those values 
falling into a linear dilution range were used to calculate infectivity. Infectivity 
was calculated by dividing the number of infected cells in a well for the 
amount of reverse transcriptase activity associated to the virus inoculum, 
measured in mU85. 
MLV was obtained by electroporation of JTAg cells and quantified by SG-PERT 
assay. MLV and glycoGag-negative MLV molecular clones, S2 and MLV-NZB-9-
1 envelope glycoproteins were used with 4:4:1 ratio, with a total amount of 
20µg of DNA. 48 hours after transfection viruses were collected and used to 
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infect TE671 cells. To increase infectivity of the virus final concentration of 8 
µg/ul of Polybrene was added to each well during infection. Four days later, 
cells were washed twice with PBS-EDTA 5mM and fixed in 2% PFA. 
Percentage of infected cells were measured by FACS and infectivity obtained 
with the same calculation mentioned described earlier. 
EIAV vector was produced in HEK293T cells by calcium phosphate co-
precipitation method, using a three-vector system composed by pEIAV53D, 
pw sin6.1 and pLG338/30 vectors with a 2:2:1 ratio and a total amount of 
30µg of DNA. Virus collection, infection of target cells, detection of infected 
cells 4 days post infection and calculation to obtain infectivity values are 
made with the same experimental procedures described for MLV.  
In all experiments involving transfection of SERINC5/3/2, 1:1.5 ratio between 
SERINC and the tested infectivity factor was used. 
In experiments in figures 2.6 and 3.8, where AP-180 C or K44A dynamin 2 
mutant were used, 1:1.5 ratio between the tested infectivity factor and each 
endocytosis inhibitors separately tested was used. 
 
SG-PERT133   
 
5 µl of 2x lysis buffer ( 0.25% Triton X-100, 50 mM KCl, 100 mM Tris HCl pH 
7.4, 40% Glycerol, 80U of Human Placenta RNase inhibitor/100 (New England 
Biolabs ), mixed with 5 µlof virus suspension or controls. After 10 minutes of 
incubation at RT, 90 µl of 1X core buffer (50 mM (NH4)2SO4, 20 mM KCl, 200 
mM Tris-HCl pH 8.3) was added. 10 µl aliquots were mixed with 10 µl of 2x 
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reaction buffer (5 mM (NH4)2SO4, 2 mM KCl, 20 mM Tris-HCl pH 8.3, 10 mM 
MgCl2, 0.2 mg/ml BSA, 1/10000 SYBR Green-I, 400 µM dNTPs, 1µM forward 
primer, 1µM reverse primer, 7 picomoles/ml MS2 RNA, 5U HotstartTaq 
(Thermo Scientific)) for RealTime PCR. RT activity for each sample was 
compared with a standard curve using viruses of known concentrations 
expressed in functional units133 (Figure 6.2). 
Infectivity 
assay 
methodology 
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Figure 6.2 
Infectivity assay methodology.  
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Immunofluorescence assay 
 
5 million JTAg cells per sample were electroporated with 20 µg of total DNA 
using the same conditions previously described. Transfected cells were 
collected after 48h and seeded on poly-L-lysine coated coverslip; COS-7 cells 
were seeded the day before transfection in 6 well plates to be 50% confluent 
at transfection, carried out by the calcium phosphate method using 5 µg of 
total DNA. 2 days later, cells were fixed in 4% PFA and permeabilised for 15 
minutes with BD Perm/Wash buffer. At this point, cells were first stained with 
a mouse anti-HA antibody diluted 1:1000 (HA.11, Covance) and then with a 
secondary antibody (Alexa 633, Life Technologies) diluted 1:500. After each 
antibody staining, 3 washes were performed with BD Perm/Wash buffer. The 
coverslips were mounted on slides using Pro Long Diamond Antifade 
Mountant (Life Thecnologies). The Images were acquired with a Leica TCS SP5 
confocal microscope. 
 
Western blotting 
 
Cell lysates and virion pellets were analyzed by SDS-PAGE and Western 
blotting. Viral particles were collected 48h after transfection, centrifuged at 
300g to remove cells debris and filtered through a 0.45 µm pore size filter. 
The clarified supernatants were overlaid on 25% sucrose cushion and 
concentrated at 100,000g for 2h. The pellets were resuspended directly in 
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Laemmli buffer supplemented with 50mM TCEP pH 7.0, normalized by 
reverse transcriptase assay (in case of virion pellets) and resolved by SDS-
PAGE. Samples were loaded on 12.5% acrylamide gel with 5mM TCEP after 5-
pulse sonication. After the electrophoretic separation (10mA constant 
current), proteins were electro-transferred on Immobilon-FL PVDF 
membrane (Millipore) with semi-dry transfer apparatus (TE22 Mighty Small 
Transphor Unit – Hoefer), for 75 minutes at 155mA, 20 Volt maximum. 
Odyssey Blocking Buffer (Li-COR) diluted 1:1 in TBS was used for blocking. 
Probing was performed using a mouse anti-HA antibody (HA.11, clone 16B12, 
Covance) or a mouse or rabbit beta-actin antibody (Li-COR) or an anti-HIV-1 
p55/p24 antibody (National Biological Standards Board); secondary antibody 
used were IRDye 680 and IRDye 800 (Li-COR). After each antibody staining, 3 
washes were performed using TBS-Tween 0,01%. Blot were imaged using a Li-
COR Odyssey infrared imaging System (Li-COR). Antibody dilutions were 
chosen according to the manufacturer recomendation85. 
Click chemistry 
 
Click assay was performed with Invitrogen Click iT Metabolic Labeling 
Reagents for Proteins, modified to our need the suggested protocol. Briefly 
40 µM of myristic acid-azide was added to cell medium 24h post-transfection 
and incubated O/N. The following day the cell pellet for each sample was 
lysed with urea lysis buffer provided with the kit supplemented with protease 
inhibitors (Roche) and 100 units of Benzonase (Sigma). After a 5 minutes 
centrifugation at 10000 rcf, lysates were added to 2x catalyst solution and to 
the resuspended resin; this preparation was kept rotating end-over-end at 
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room temperature over-night. The day after, the reaction was centrifuged for 
1 minute at 1000g to separate the resin from the supernatant. After a wash 
with water, SDS wash buffer supplemented with 10 mM DTT was added to 
the resin, followed by a step of heating at 70°C and cooling at room 
temperature for 15 minutes. Then resin was centrifuged again, resuspended 
in water and allowed to pass through a column. After 5 washing with washing 
buffer supplemented with 1M Urea, one last wash was performed with 8M 
urea, 100 mM Tris pH8. 
At this point, resin was collected and directly resuspended in 2x Laemmli 
buffer to perform a SDS-PAGE. 
Human influenza A virus production  
 
Reverse genetics systems for the following influenza virus strains were used 
in this study. Virus stocks were generated in MDCK cells with infection media 
(serum free DMEM) supplemented with 1% Penicillin-Streptomycin and 1 
μg/ml TPCK-treated trypsin (Lorne Labs) and incubated at 37 °C. Clinical 
isolate A/Victoria/3/75 and the A/England/195/2009 (Public Health England) 
was propagated in MDCK cells with infection media. Aliquots of infectious 
virus were stored at −80 °C. Infectious titres were determined by plaque 
assay on MDCK cells. 
Influenza A virus infection 
 
HEK293T cells were seeded the day before in 24 well plates to be 70–90% 
confluent at transfection, and then transfected with SERINC 5/3/2 HA PBJ6 or 
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IFITM3, using 1.5 µg of total DNA according to the Lipofectamine 3000 
manufacturer recommendation (Invitrogen).  After 20 h infection with virus 
diluted in serum-free DMEM for 1 h at 33 °C or 37 °C, medium was replaced 
with DMEM supplemented with 0.1% FCS and 1 μg/ml TPCK trypsin 
(Worthington-Biochemical) (for infectious virus titres). 3.1x107 MOI and 
3.9x107 MOI were used respectively for A/Victoria/3/75 and 
A/England/195/2009. Infected cell lysates and cell supernatants were 
harvested at 24h post-infection. Infectious titres were determined by plaque 
assay on MDCK cells. 
 
Plaque assay 
 
Six different 10-fold serial dilutions of each virus obtained in triplicates, were 
used to infect in duplicate 90% confluent MCDK cells previously washed twice 
in PBS. Viruses were kept incubating with cells for 1 hour at 37°C, and then 
they were removed and replaced with 1 ml of overlay media (DMEM high 
glucose with 4 to 6 mM glutamine and 2% fetal bovine serum, 2.3 µg/ml flu 
trypsin) mixed with an appropriate volume of oxoid high purified 2% agarose 
solution. Plates were left in a humidified incubator at 37°C and 5% CO2 for 
three days to allow the plaques formation (Figure 6.3). 
Real-Time PCR 
 
Viral RNA was extracted from the supernatant of cells infected with 
A/England/195/2009 in the presence of SERINC5 or pcDNA 3.1 negative 
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control using QIAamp Viral RNA extraction Kit according to the manufacturer 
instructions (QIAGEN). 1 µl of the obtained viral RNA was used as template 
for a retro-transcription reaction using SuperScript III First-Strand Synthesis 
System for RT-PCR kit (Thermo Fisher) and oligo(dT) primer. 
 Equal volumes of cDNA for each sample were used to set-up a SYBR green 
based qPCR. Matrix gene from the genome of influenza was used to 
normalize the viral particle release. 
 
Safety/biosecurity 
 
All experiments with infectious agents were conducted in biosafety level 2+ 
facilities, approved by the Health and Safety Executive of the UK and in 
accordance with local rules, at Imperial College London, UK. 
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Figure 6.3  
Plaque assay methodology. 
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 Table 2:  Primers for generation of chimeric  
glycoGag constructs 
  
Name Sequence 
PERV Fw 
NotI 
 
ATATATGCGGCCGCAACCATGGGAGACGTCCCAGGGACTT 
 
PERV rev 
AflII 
 
GGTCAAACTTAAGGGGGTAGTCACTGTCTGTCC 
 
FeLV fw 
NotI 
 
TTACGCTGCGGCCGCAACCATGTCTGGAGCCTCTAGTG 
 
FeLV rev 
AflII 
 
GGTGAGGCTTAAGGGGGTAGTTATAGTTTGGCC 
 
GALV fw 
NotI 
 
AAAAAAGCGGCCGCCATGACCCGATTTCATCGCCCGTCTGG 
 
GALV rev 
AflII 
 
ATATATCTTAAGGGGGCAGAAGTACCTTGTCC 
 
KoRV fw 
NotI 
 
AGGGAGACCCAAGCTGGCGGCCGCCGCCATGGGAGACGTCCCAGGA 
 
KoRV rev 
AflII 
 
GTCAAACTTAAGGGGGTCGACTCACCCTGTC 
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Table 3:  Primers for codon optimization and 
mutagenesis 
 
Name Sequence 
S2 V3L co fw CGAGGCCACCATGGGGCTCTTCGGCAAGGGAGTGACTTG
G 
S2 V3L co rev CCAAGTCACTCCCTTGCCGAAGAGCCCCATGGTGGCCTCG 
S2 E18G fw GCCAGCCACAGCATGGGAGGATCCCAGGGCGAAAGCCAG 
S2 E18G fw CTGGCTTTCGCCCTGGGATCCTCCCATGCTGTGGCTGGC 
S2 Co fw ATATATCTCGAGGCCACCATGGGCGTGTTCGGCAAGGGA
GTGACTTGGAGCGCCAGCC 
MCS-S2 rev ACACGCCCATGGTGGCCTCGAGCTCGAGTCTAGAGGGCC
CGTTTAAAC 
S2 Co rev 1 GTGGCTGGCGCTCCAAGTCACTCCCTTGCCGAACACGCCC
ATGGTGGCCTCGAG 
S2 Co rev 2 GGGCAGCAGGGGCTGGCTTTCGCCCTGGCTCTCTCCCATG
CTGTGGCTGGCGCTCCAAG 
S2 Co rev 3 GGTTGAAGCACTGGGTCCGCCGCACGCTCAGGTTTTTCTG
GCTGTTGGGCAGCAGGGGC 
S2 Co rev 4 CCGCCGGTTCTGCCAGGCGGTCCGCACGGTCATGATGATC
ACGATCAGGTTGAAGCACT 
S2 Co rev 5 CGTCGTAGGGGTATTTCTTTGTTTCCTGCTTCCGCCGGTTC
TGCC 
S2 Co rev 6 GTGGTGGAATTCAGGCGTAGTCGGGCACG 
S2 Co LLAA mut fw GGGCGAAAGCCAGCCGGCCGCGCCCAACAGCCAG 
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S2 Co LLAA mut rev CTGGCTGTTGGGCGCGGCCGGCTGGCTTTCGCCC 
S2 Co GA mut fw CTCGAGGCCACCATGGCCGTCTTCGGCAAGGGAGTG 
S2 Co GA mut rev CACTCCCTTGCCGAAGACGGCCATGGTGGCCTCGAG 
S2 Co PPAA mut fw CAGGGCGAAAGCCAGGCCTTACTGGCCAACAGCCAGA 
S2 Co PPAA mut rev TCTGGCTGTTGGCCAGTAAGGCCTGGCTTTCGCCCTG 
S2 Co TM mut fw GACCCAGTGCTTCAACTCTAGCGTCTCATCAATGACCGTGC
GGACCG 
S2 Co TM mut rev CGGTCCGCACGGTCATTGATGAGACGCTAGAGTTGAAGC
ACTGGGTC 
OrfA CO fw 
 
TCTAGACTCGAGCCACCATGG 
 
OrfA R 01 
 
GGTCACGCGGTTGAACAGCACGATGATATCTTCCATGGTG
GCTCGAGTCTAGAGGGCCC 
 
OrfA R 02 
 
AGCACGAAGATCCGGATGGCCAGCTCTTTTTCCAGCTTCTC
GGTCACGCGGTTGAACAG 
 
OrfA R 03 
 
GCAGCAGTCTGATGGCCTTGTCCCGTTCCAGCTGGTGGGC
CAGCACGAAGATCCGGATG 
 
OrfA R 04 
 
CACCCGGGGTTTCTTGAATCTGTACCGCCAGAACAGGCCC
TGCAGCAGTCTGATGGCCT 
 
OrfA R 05 
 
CAGTAGTAGAACTTGCAGCACCACCAGCACAGGCAGTAG
TCCACCCGGGGTTTCTTGAA 
 
OrfA R 06 
 
GTGATGCTCAGGGTGCTCTGCAGCTGCCAGTAGTAGAACT
TGCAG 
 
OrfA R 07 CGTCCTTGTAGTCGGCGGTGGTGATGCTCAGGGTGCT 
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OrfA R 08 FLAG 
 
ATATATGAATTCTCACTTGTCGTCGTCGTCCTTGTAGTCGG
CG 
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Table 4: Cell lines description 
 
Cell  line Cell type Source 
Jurkat TAg (JTAg) T Lymphocyte, Acute T 
Cell Leukemia 
Heinrich Gottlinger, DFCI, 
Harvard University 
CEMX174 Limphocytes, fusion 
between a Bcell line 
and a human T cell line 
NIH AIDS Research and 
reference Reagent program 
HEK293T Epithelial, embryonic 
Kidney 
ECACC 
TE671 Rhabdomyosarcoma Yasuhiro Takeuki, UCL, London 
TZM-bl HeLa cell line  
generated from JC.53 
cells by introducing 
separate integrated 
copies of the luciferase 
and ß-galactosidase 
genes under control of 
the HIV-1 promoter. 
NIH AIDS Research and 
reference Reagent program 
COS-7 Cercopithecus aethiops, 
Kidney 
ATTC 
MDCK Madin Darby Canine 
Kidney  
ATTC 
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